WO2014139330A1 - Rapid genotyping analysis and kits thereof - Google Patents
Rapid genotyping analysis and kits thereof Download PDFInfo
- Publication number
- WO2014139330A1 WO2014139330A1 PCT/CN2014/000275 CN2014000275W WO2014139330A1 WO 2014139330 A1 WO2014139330 A1 WO 2014139330A1 CN 2014000275 W CN2014000275 W CN 2014000275W WO 2014139330 A1 WO2014139330 A1 WO 2014139330A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nos
- amplicons
- oligonucleotide probes
- primers
- Prior art date
Links
- 238000003205 genotyping method Methods 0.000 title abstract description 16
- 238000004458 analytical method Methods 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 142
- 244000052769 pathogen Species 0.000 claims abstract description 66
- 230000035772 mutation Effects 0.000 claims abstract description 63
- 239000000523 sample Substances 0.000 claims abstract description 48
- 208000019802 Sexually transmitted disease Diseases 0.000 claims abstract description 43
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 41
- 206010020608 Hypercoagulation Diseases 0.000 claims abstract description 24
- 201000005665 thrombophilia Diseases 0.000 claims abstract description 24
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims abstract description 23
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims abstract description 21
- 238000009396 hybridization Methods 0.000 claims description 106
- 150000007523 nucleic acids Chemical class 0.000 claims description 75
- 108020004707 nucleic acids Proteins 0.000 claims description 72
- 102000039446 nucleic acids Human genes 0.000 claims description 72
- 108091093088 Amplicon Proteins 0.000 claims description 71
- 239000002751 oligonucleotide probe Substances 0.000 claims description 56
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 55
- 208000005980 beta thalassemia Diseases 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 241000589884 Treponema pallidum Species 0.000 claims description 13
- 101150013110 katG gene Proteins 0.000 claims description 11
- 101150090202 rpoB gene Proteins 0.000 claims description 11
- 241000701806 Human papillomavirus Species 0.000 claims description 10
- 101150005343 INHA gene Proteins 0.000 claims description 10
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 claims description 10
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 claims description 10
- 108010094028 Prothrombin Proteins 0.000 claims description 10
- 108010091897 factor V Leiden Proteins 0.000 claims description 9
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 7
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 6
- 241001428582 Human papillomavirus type 6 Species 0.000 claims description 6
- 241000204051 Mycoplasma genitalium Species 0.000 claims description 6
- 241000204048 Mycoplasma hominis Species 0.000 claims description 6
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 6
- 241000224527 Trichomonas vaginalis Species 0.000 claims description 6
- 241000935255 Ureaplasma parvum Species 0.000 claims description 6
- 241000202921 Ureaplasma urealyticum Species 0.000 claims description 6
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 6
- 102100027378 Prothrombin Human genes 0.000 claims description 5
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 5
- 229940039716 prothrombin Drugs 0.000 claims description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 14
- 238000001514 detection method Methods 0.000 description 46
- 238000003752 polymerase chain reaction Methods 0.000 description 40
- 108020004705 Codon Proteins 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 36
- 238000012360 testing method Methods 0.000 description 36
- 230000003321 amplification Effects 0.000 description 25
- 238000003199 nucleic acid amplification method Methods 0.000 description 25
- -1 AMINO Chemical class 0.000 description 19
- 230000001717 pathogenic effect Effects 0.000 description 18
- 238000012408 PCR amplification Methods 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 14
- 239000013641 positive control Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 12
- 229960001225 rifampicin Drugs 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 101100038261 Methanococcus vannielii (strain ATCC 35089 / DSM 1224 / JCM 13029 / OCM 148 / SB) rpo2C gene Proteins 0.000 description 8
- 101100509674 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) katG3 gene Proteins 0.000 description 8
- 101150085857 rpo2 gene Proteins 0.000 description 8
- 201000008827 tuberculosis Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 6
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 208000028782 Hereditary disease Diseases 0.000 description 4
- 206010043391 Thalassaemia beta Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000012807 PCR reagent Substances 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 208000005448 Trichomonas Infections Diseases 0.000 description 3
- 206010044620 Trichomoniasis Diseases 0.000 description 3
- 238000007844 allele-specific PCR Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011896 sensitive detection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 2
- 206010055690 Foetal death Diseases 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 208000008899 Habitual abortion Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000012442 inherited thrombophilia Diseases 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-ZXFLCMHBSA-N 5-[(3ar,4r,6as)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@H]2[C@@H](CCCCC(=O)O)SC[C@H]21 YBJHBAHKTGYVGT-ZXFLCMHBSA-N 0.000 description 1
- 208000009206 Abruptio Placentae Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 241000582786 Monoplex Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 101150087129 mtb gene Proteins 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 201000008532 placental abruption Diseases 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000035203 thalassemia minor Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/52—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/5215—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data
- A61B8/5223—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for extracting a diagnostic or physiological parameter from medical diagnostic data
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/42—Details of probe positioning or probe attachment to the patient
- A61B8/4209—Details of probe positioning or probe attachment to the patient by using holders, e.g. positioning frames
- A61B8/4236—Details of probe positioning or probe attachment to the patient by using holders, e.g. positioning frames characterised by adhesive patches
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention is related to the field of identification of various genotypes associated with human diseases.
- the present invention is related to identification of various genotypes.
- Various techniques such as sequence-specific primers polymerase chain reaction (SSP-PCR), DNA sequencing, DNA fingerprinting and single nucleotide polymorphism (SNP) genotyping have been employed for genotyping (PCT Application Publication WO/201 1 / 1 39750).
- SSP-PCR sequence-specific primers polymerase chain reaction
- DNA sequencing DNA sequencing
- DNA fingerprinting DNA fingerprinting
- SNP single nucleotide polymorphism
- SNP genotyping is more advantageous for its higher discrimination power.
- most genotyping assays involve hybridization processes of DNA which require high running cost and hand-on time. Therefore, there is a need to develop more effective genotyping assays which are faster, cheaper andable to cover more genotypes.
- Tuberculosis is caused by Mycobacterium tuberculosis (MTB).
- MTB Mycobacterium tuberculosis
- DR-MTB multidrug-resistant tuberculosis
- RIF rifampin
- INH isoniazid
- DST phenotypic Drug susceptibility testing
- Mycobacterium tuberculosis is a slow-growing bacterium. It divides every 15-20 hours and it takes from 4 to 6 weeks to grow the colonies depending on the medium used. After that, when MTB culture is identified, drug susceptibility test will be performed which usually takes 2 additional weeks. The test hence requires a long hand-on time and leads to delay treatment of the disease if therapy starts after diagnosis is completed. Therefore, the usual practice is to begin the treatment before the results are confirmed.
- the present invention provides an array test that can simultaneously detect single-drug and multi-drug resistant types of MTB in one platform with a much shorter detection time (-35 min) than the conventional hybridization.
- the whole test would need less than 4 hours, from DNA extraction from samples to analysis, and gives highly specific and sensitive results.
- Beta Thalassemia is a common hemoglobinopathy that is caused by autosomal mutations, which can be sub-divided into categories depending on the extent to which beta-globin production is affected. Some mutations result in mild reductions in the production of beta-globin (denoted as ⁇ + ), whereas some cause absolute silencing of the beta-globin gene, or the production of non-functional beta-globin (denoted as ⁇ °). It is estimated that around 1 .5% of the world's population are beta-thalassemia heterozygotes, or carriers, and the coupling of two carriers may produce offsprings that are homozygous for the disease.
- Beta-thalassemia is endemic in temperate regions such as Mediterranean countries, Middle East and Southeast Asia. The molecular bases for beta-thalassemia has been extensively studied and micro-mapped to point mutations along the beta-globin gene. Different geographic regions have different mutation spectra, and the frequency of mutations is not homogeneous in each region.
- Microarray can detect multiple targets simultaneously on a DNA chip and hence applicable for detecting multiple samples simultaneously.
- AS-PCR Allele-specific PCR
- Allele-specific PCR is a PCR technology using allele-specific primer to detect polymorphism or mutation in which only the perfectly matched oligonucleotide is able to act as a primer for amplification.
- the limitation of this technology is the limited throughput in one reaction.
- the present invention provides a DNA testing using a combination of PCR and reverse dot blot hybridization which offers a highly sensitive and specific detection of beta-globin gene mutation, assisting diagnosis of beta-thalassemia.
- HBV is the smallest DNA virus comprising 3000 nucleotides surrounded by a protein capsid. It can be transmitted through contact with blood or body fluids of an infected individual. Approximately 2 billion people are infected with HBV; in which over 350 million become HBV carriers. About one-fifth would develop HBV-related cirrhosis or eventually liver cancer. Detection of HBV can be diagnosed by surface antigen using simple blood tests and HBV DNA measurement using polymerase chain reaction (PCR). In addition, analysis of the divergence of HBV genome sequences has led to the identification of 10 HBV genotypes (A to J) and several subtypes. HBV genotypes and subtypes show a distinct geographical distribution.
- HBV genotypes It has been discovered that pathogenic and therapeutic differences exist among various HBV genotypes.
- the determination of HBV genotypes can provide information for the management of chronic HBV infection and pre-treatment evaluation.
- DNA sequencing has been considered as the gold standard method for the detection of HBV genotypes. However, it is less efficient in detecting mixed genotypes.
- using molecular DNA techniques has offered a highly sensitive and specific method for HBV genotype detection.
- STDs sexually transmitted diseases
- WHO estimates 448 million new cases of curable STDs (syphilis, gonorrhoea, chlamydia and trichomoniasis) occur annually throughout the world in adults aged 15-49 years.
- STDs can infect her baby before, during, or after the baby's birth.
- Untreated gomorrhea and chlamydia may result in infertility. Therefore, pre-married couples and pre-pregnancy women are also potential users of STDs detection.
- Thrombophilia is an abnormality of blood coagulation that increases the risk of thrombosis.
- SNP genotyping can be utilized for identification of gene fragments, or polymorphism of genes that have altered or attenuated the function of the gene in question.
- the present invention provide methods and kits for rapid, definitive identification of infectious agents, inherited disease caused by the specific DNA sequences, or the presence or absence of such infectious agents or DNA sequences that cause inherited diseases.
- ASO-RDB membrane-based micro-array Allelic-Specific-Oligonucleotide Reversed-Dot-Blotting
- DNA hybridization has been the most essential method for research in modern biological science involving the molecular studies of genes.
- the complexity of nucleic acid sequences of various genomes were revealed by solution hybridization through the annealing process of the complementarity of specific DNA sequences.
- the DNA in question is amplified or digested, and allowed to hybridize with complementary DNA probes on a solid support such as a nitrocellulose membrane.
- a solid support such as a nitrocellulose membrane.
- immobilization and hybridization techniques are in principle limited by the area of the membrane, and usually involve long incubation time.
- flow-through hybridization methods and devices which can accurately control the hybridization conditions have been developed.
- the flow-through DNA hybridization method and device reduce hybridization time from many hours or days to minutes (the whole hybridization assay can be completed in 5-30 m inutes depending the method used to generate detection signal).
- the device is also inexpensive to manufacture, and uses 10 times less reagents than conventional hybridization devices which will lead to more affordable DNA diagnosis technology.
- Flow-through hybridization technology also gives more sensitive and accurate results of detection/identification, and can be universally applied to various techniques such as conventional Southern, Northern, Dot-Blot, Slot-Blot and Reversed-Dot Blot hybridization. Because of its higher efficiency, accuracy and sensitivity, flow-through hybridization is more advantageous in comparison to conventional hybridization techniques.
- PCT application WO/201 1 / 139750 describes multiple lateral flow-through detection devices connected to a central control unit.
- the hybridization device comprises a central controlling unit connected to one or more lateral flow device.
- the central controlling unit provides power to and controls the lateral flow device where the hybridization process and developing procedures are carried out.
- Several reactions or several samples and/or analytes) can be tested simultaneously in a single lateral flow device or in several devices (controlled individually at different conditions) at the same time.
- the lateral flow device can be in a format of 'n x m' dot matrix (array) or in the form of linear arrays. More descriptions on methods and devices for performing flow-through hybridization can be found in the U.S. Patent No.
- This invention provides method and kit to detect rifampicin (RIF) and isoniazid (INH) resistant strains of Mycobacteriu Tuberculosis (MTB) using Polymerase Chain Reaction (PCR) and "Flow-through” hybridization technology. Mutation of the MTB gene encoding beta subunit of RNA polymerase (rpoB) is found associated with rifampin resistance, while mutation in genes katG and InhA, which respectively encode for catalase peroxidase and enoyl-ACP-reductase, are reported to be associated with isoniazid resistance.
- primers specific to rpoB, katG and InhA are used to amplify corresponding genes, and they have been verified not cross-reacting with human genome.
- Primer RS-IAC which does not target at any human or MTB genome, serves as an internal amplification control for monitoring the PCR amplification process.
- Ten mutation DNA probes are included for detection of drug resistant mutations in rpoB (D516V, D516G, H526D, H526Y, H526L 1 , S53 1 L and S53 1 W), katG (S3 15T 1 and S315T2), and inhA (-15TC/T).
- the primers can be biotinylated for hybridization. Beta Thalassemia Detection
- This invention provides method and kit for the detection of beta-globin mutations including TATA -28 (A>G), TATA -29 (A>G), Initiation Codon (G>A), Codon 5 (-CT), Codons 8/9 (+G), Codon 15 (G>A), Codon 16 (-C), Codon 17 (A>T), Codon 19 (A>G), Codon 26 (G>A) (Hb E), Codons 27/28 (+C), Codon 30 G>C, IVS 1 .1 (G>T), 1VS 1.1 (G>A), 1VS 1.5 (G>C), Codons 41/42 (-TCTT), Codon 43 (G>T), Codons 71/72 (+A), IVS2.1 (G>A), IVS2.654 (OT), and 619 bp deletion.
- This invention provides method and kit to detect the presence of 8 HBV genotypes (HBV Genotypes A, B, C, D, E, F, G and H) in human serum samples.
- 8 HBV genotypes HBV Genotypes A, B, C, D, E, F, G and H
- This invention provides method and kit to detect the presence of protozoa, bacteria and viruses in various specimens such as urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCytTM and SurePathTM).
- Amplification Control is included for detection of human DNA materials to check for the presence of sufficient cellular content and validity of the results. AC can be used to monitor the presence of PCR inhibitors and the presence of sufficient amount of extracted DNA during PCR amplification. Absence of Amplification Control signal may indicate either failure of the PCR amplification (PCR inhibitor present) or insufficient amount of DNA (or absence of specimen) during PCR amplification.
- PC Positive Control
- DNA hybridization and PCR technologies enable a faster detection of STD-causing pathogens in urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCytTM and SurePathTM).
- the method and kit can detect the presence of 12 common pathogens: 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genital ium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ). These pathogens are related to cervicitis, urethritis, trichomoniasis and pelvic inflammatory disease.
- 1 protozoan Trichomonas vaginalis
- 7 bacteria Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genital ium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema
- the present invention provides universal primers and pathogen-specific primers for detecting STD-causing pathogens.
- Universal primers are used to achieve a balanced amplification among different targets in the multiplex PCR. Sequences were tested by PCR and gel electrophoresis on their specificity on pathogen targets and human DNA to prove that they do not cross-react with other pathogens and human genome. Two universal sequences that do not cross-react with the pathogen targets and human DNA were designed and added to the 5 'end of pathogen specific primers. The same was done to the AC specific primers.
- the resulting universal primers and pathogen-specific primers tagged with the universal sequences were further tested by PCR and gel electrophoresis and proven not cross-reacting with other pathogens and human genome ( Figure 1 ).
- pathogen-specific primers tagged with universal sequences and two universal primers were included in a single PCR.
- pathogen-specific primers bind to their specific target and create a PCR product carrying the universal sequence.
- the universal primers bind to the universal-sequence-tagged PCR products ( Figure 2). Under an optimized PCR condition, we can achieve a balanced amplification and avoid the loss of amplification due to different amplification efficiencies of different pathogen targets.
- the universal primers system described herein can be also applied to other methods and kits detecting nucleic acids or gene associated with DR-MTB, Beta-globin, HBV and thrombophilia, and also other diseases or conditions that are not described in the present invention.
- This invention provides method for the identification of gene variants related to inherited thrombophillia, including Factor V Leiden (FVL) [ 1691 G>A], Factor II (Prothrombin)
- FVL Factor V Leiden
- Prothrombin Factor II
- MTHFR Methylenetetrahydrofolate Reductase
- MTHFR Methylenetetrahydrofolate Reductase
- PCR was used for amplification in the data validating examples, any method that can produce specific target sequence(s) in sufficient quantity for the identification and flow-through hybridization analysis may be used. Amplification may not be necessary if sufficient quantity of the target sequence(s) can be obtained for the identification and analysis. Detection can be accomplished by labeling of the target DNA or conjugates.
- Figure la shows an electrophoretic image of PCR reactions on human clinical samples using universal primers (SEQ ID NO. 285 and 286). Specific bands are only observed in positive samples in which the pathogens are present (i.e. CT-positive, NG-positive, HPV-6 and HPV-11 positive), indicating that the universal primers do not cross react with human DNA.
- Figure lb shows an electrophoretic image of PCR reactions on human clinical samples using pathogen-specific primers (SEQ ID NO. 263-282) and universal primers (SEQ ID NO. 285 and 286). Specific bands are observed in each sample in which the corresponding pathogens are present, indicating that the primers are highly specific to their respective pathogens. Similar observation can be found in both monoplex and multiplex PCR reactions.
- Figure 2 shows one embodiment of a PCR amplification scheme using Universal primers and gene-specific primers in one single reaction.
- Figure 3 shows one embodiment of DR-MTB cassette (left panel) and signal position (right panel) (grids shown for illustration purpose only) for DR-MTB detection.
- IAC is the internal amplification control for monitoring PCR Amplification process.
- HC is the hybridization control which monitors the hybridization process. Validity of PCR amplification and specimen are also accessed by various controls.
- Figure 4 shows one example of visual interpretation of different MTB mutants.
- Figure 5 shows one embodiment of beta-thalassemia cassette and signal position (grids shown for illustration purpose only).
- Figure 6a shows one example of visual interpretation of different beta-thalassemia genotypes.
- Figure 6b shows testing results on various clinical samples using the beta-thalassemia cassette.
- FIG 7 shows one embodiment of a HBV test kit detecting the presence of 8 HBV genotypes (HBV A, B, C, D, E, F, G and H). Universal primer, IAC and HC are also included.
- Figure 8 shows one example of visual interpretation of different HBV genotypes.
- Figure 9a shows a comparison of sensitivity of the present invention and a STD testing kit from other manufactory.
- Figure 9b shows a side-by-side comparison of performance of the present invention and an STD testing kit from other manufactory on clinical samples.
- Figure 10a shows one embodiment of a STD array, cassette format and signal position.
- the array can detect the presence of 12 common pathogens: 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ).
- Amplification Control is used to monitor the presence of PCR inhibitors and the presence of sufficient amount of extracted DNA during PCR amplification.
- Treponema pallidum can be provided as a positive control (PC) which contains a positive template to monitor the performance of PCR reagents.
- Figure 10b shows one example of visual interpretation of the STD array.
- Figure 11 shows one embodiment of a Thrombophilia array.
- Figure 12 shows one example of visual interpretation of the Thrombophilia array.
- Allelic-Specific-Oligonucleotide Reversed-Dot-Blotting refers to assays using Allelic-Specific-Oligonucleotide probes immobilized on a solid matrix capable of capturing target molecules for detection through hybridization processes.
- flow-through hybridization refers to the hybridization process utilizing the technology described in U.S. Patent No. 5,741 ,647.
- flow-through hybridization device or “flow-through device” refers to the device depicted in U.S. Patent No. 6,020, 187 and/or the lateral flow device depicted in PCT application WO/201 1 /139750 or any flow-through device designed subsequently.
- the present invention provides methods, primers, probes and kits for identification and/or W detection of various nucleic acids, mutations, agents, pathogens and/or diseases.
- the present invention is applied to detecting the presence of Tuberculosis, HBV, HCV, SARS, respiratory infectious viruses, sexually-transmitted diseases-causing agents, beta-globin, thrombophilia and/or the nucleic acids associated thereof, individually or in combinations.
- the method involves PCR amplification using specific primers to generate amplicons, hybridizing said amplicons with oligonucleotide probes. The resulting hybridization profile would indicate the presence of the nucleic acids, mutations, agents, pathogens and/or diseases in question.
- the hybridization of the amplicons with oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
- the oligonucleotide probes are immobilized for hybridization.
- the sensitivity of the hybridization depends on the ratio of the area comprising the probes to the total area of the membrane of the array.
- the sensitivity of the hybridization depends on the ratio of the cross-sectional area comprising the probes to the total cross-sectional area of the membrane across the flow direction.
- the present invention provides a method for detecting the presence of nucleic acid and/or exogenous agent in a subject, comprising the steps of: (a) amplifying a template nucleic acid from a sample obtained from the subject with primers selected from SEQ ID NOs: 174-181 , 201 -205, 241 -244, 263-286 and 299-306 to generate amplicons, alone or in combination thereof; and (b) hybridizing said amplicons with oligonucleotide probes selected from SEQ ID NOs: 182-200, 206-240, 245-260, 287-298, and 307-314, alone or in combination thereof wherein the resulting hybridization profile would indicate the presence of nucleic acid and/or exogenous agent in said subject.
- the present invention provides a method for detecting the presence of nucleic acid and/or exogenous agent in a subject, comprising the steps of: (a) amplifying a template nucleic acid from a sample obtained from the subject with primers selected from SEQ ID NOs: 174-181 , 201 -205, 241 -244, 263-286 and 299-306 to generate sufficient amplicons, alone or in combination thereof; and (b) hybridizing said amplicons with oligonucleotide probes selected from SEQ ID NOs: 182-200, 206-240, 245-260, 287-298, and 307-314, alone or in combination thereof wherein the resulting hybridization profile would indicate the presence of nucleic acid and/or exogenous agent in said subject.
- the present invention provides a method for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs: 174- 181 , thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs: 182-200, wherein the resulting hybridization profile would indicate the presence of multidrug-resistant Mycobacterium tuberculosis or nucleic acid of DR-MTB.
- DR-MTB multidrug-resistant Mycobacterium tuberculosis
- the method for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB comprises the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs: 174-181 , thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs: 182-200, wherein the resulting hybridization profile would indicate the presence of multidrug-resistant Mycobacterium tuberculosis or nucleic acid of DR-MTB.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
- the above methods can detect the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB having one or more of the following mutations: one of seven mutations in the rpoB gene; one of two mutations in the katG gene; and one mutation in the inhA gene.
- the present invention also provides a kit for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB, comprising primers selected from the group consisting of SEQ ID NOs: 174-181 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 1 82-200.
- the kit for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB comprises primers of SEQ ID NOs: 174- 181 and oligonucleotide probes of SEQ ID NOs: 182-200.
- the present invention also provides a method of detecting beta-globin mutations in a subject having beta-thalassemia, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:201 -205, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:206-240, wherein the resulting hybridization profile would indicate the genotypes of beta-thalassemia.
- the method of detecting beta-globin mutations in a subject having beta-thalassemia comprises the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:201 -205, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:206-240, wherein the resulting hybridization profile would indicate the genotypes of beta-thalassemia.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process and/or related devices.
- the above method of detecting beta-globin mutations can detect one of twenty one beta-globin mutations.
- the present invention also provides a kit for detecting beta-globin mutations, comprising primers selected from the group consisting of SEQ ID NOs:201 -205 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 206-240.
- the kit for detecting beta-globin mutations comprises primers of SEQ ID NOs:201 -205 and oligonucleotide probes of SEQ ID NOs: 206-240.
- the present invention also provides a method for detecting the presence of HBV, or nucleic acid of HBV, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:241 -244, thereby generating HBV amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:245-260, wherein the resulting hybridization profile would indicate the presence of HBV or nucleic acid of HBV.
- the method for detecting the presence of HBV, or nucleic acid of HBV comprises the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:241 -244, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:245-260, wherein the resulting hybridization profile would indicate the presence of HBV or nucleic acid of HBV.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
- the above method can detect the presence of HBV or nucleic acid of HBV, having a genotype selected from the group consisting of HBV genotypes A to H.
- the present invention also provides a kit for detecting the presence of HBV or nucleic acid of HBV, comprising primers selected from the group consisting of SEQ ID NOs:241 -244 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 245-260.
- the kit for detecting the presence of HBV or nucleic acid of HBV comprises primers of SEQ ID NOs:241 -244 and oligonucleotide probes of SEQ ID NOs: 245-260.
- the present invention also provides a method for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:263-286, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:287-298, wherein the resulting hybridization profile would indicate the presence of nucleic acid originated from pathogens that may develop into disease, namely sexually transmitted diseases.
- the present invention provides a method for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:263-286, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:287-298, wherein the resulting hybridization profile would indicate the presence of nucleic acid originated from pathogens that may develop into disease, namely sexually transmitted diseases.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
- the method for detecting the presence of sexually transmitted diseases causing pathogens can detect the presence of sexually transmitted diseases caused by an organism selected from the group consisting of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum, Herpes simplex virus 1 , Herpes simplex virus 2, Human papillomavirus type 6, and Human papillomavirus type 1 1 .
- the present invention also provides a kit for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject, comprising primers selected from the group consisting of SEQ ID NOs:263-286 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 287-298.
- the kit for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject comprises primers of SEQ ID NOs:263-286 and oligonucleotide probes of SEQ ID NOs: 287-298.
- the present invention also provides a method for detecting mutations related to thrombophilia, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:299-306, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:307-314, wherein the resulting hybridization profile would indicate the presence of mutations related to thrombophilia.
- the primers comprise a signal generating label.
- the method for detecting mutations related to thrombophilia comprises the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:299-306, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:307-3 14, wherein the resulting hybridization profile would indicate the presence of mutations related to thrombophilia.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
- the method for detecting mutations related to thrombophilia can detect mutation at a gene selected from the group consisting of Factor V Leiden, Factor II (Prothrombin), and Methylenetetrahydrofolate Reductase.
- the present invention also provides a kit for detecting the presence of mutations related to thrombophilia, comprising primers selected from the group consisting of SEQ ID NOs:299-306 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 307-3 14.
- the kit for detecting the presence of mutations related to thrombophilia comprises primers of SEQ ID NOs:299-306 and oligonucleotide probes of SEQ ID NOs: 307-314.
- the present invention provides methods and array test kits for DR-MTB genotyping.
- the methods and kits are designed to detect rifampicin (RIF) and isoniazid (INH) resistant strains of Mycobacterium Tuberculosis (MTB) using Polymerase Chain Reaction (PCR) and "Flow-through” hybridization technology.
- Primers specific to rpoB, katG and InhA are used to amplify corresponding genes, and they have been verified not cross-reacting with human genome.
- Primer RS-IAC is an internal amplification control which does not target at human or MTB genome but serves as an internal amplification control for monitoring the PCR amplification process.
- Ten mutation probes are included for detection of drug resistant mutations in rpoB (D516V, D516G, H526D, H526Y, H526L 1 , S53 1 L and S531 W), katG (S315T1 and S3 15T2), and inhA (- 15TC/T).
- Five wild-type MTB probes are also included for detection of wild-type MTB variants, which helps to validate if the PCR reaction and amplification of rpoB, katG and inhA genes have been successfully performed.
- the primers are biotinylated for hybridization.
- the present invention provides a method for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs: 174- 18 1 , thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs: 182-200, wherein the resulting hybridization profile would indicate the presence of multidrug-resistant Mycobacterium tuberculosis.
- DR-MTB multidrug-resistant Mycobacterium tuberculosis
- the present invention can detect the presence of multidrug-resistant Mycobacterium tuberculosis having one or more of the following mutations: one of seven mutations in the rpoB gene; one of two mutations in the katG gene; and one mutation in the inhA gene.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
- Figure 3 shows one embodiment of DR-MTB cassette (left panel) and the respective positions of probes and signals (right panel). IAC is the internal amplification control for monitoring PCR amplification process.
- HC is the hybridization control which monitors the hybridization process.
- Figure 4 shows one embodiment of DR-MTB array profile for DR-MTB detection.
- RIF and ⁇ resistant strains of MTB are detected separately.
- MTB strains resistant to both RIF and 1NH are detected (multi-drug resistant).
- strains that are neither resistant to rifampicin (RIF) nor isoniazid (INH) are detected (out of panel mutation).
- Validity of PCR amplification and specimen are also accessed by various controls. Primer Sequences
- Probe Sequences Probe Probe sequence (5'-3') 5' Modification SEQ ID NO TB-DR-Rpob-CTRL GCTGGTGCCGAAGAA AMINO 1 82
- This invention provides a system for the detection of beta-globin mutations including TATA-28 (A>G), TATA-29 (A>G), Initiation Codon (G>A), Codon 5 (-CT), Codons 8/9 (+G), Codon 15 (G>A), Codon 16 (-C), Codon 17 (A>T), Codon 19 (A>G), Codon 26 (G>A) (Hb E), Codons 27/28 (+C), Codon 30 G>C, IVS l . l (G>T), IVS l .
- the present invention also provides a method of detecting beta-globin mutations in a subject having beta-thalassemia, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:201 -205, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:206-240, wherein the resulting hybridization profile would indicate the genotypes of beta-thalassemia.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
- the above method can detect one of twenty one beta-globin mutations.
- Figure 5 shows one embodiment of beta-thalassemia cassette and signal position (grids shown for illustration purpose only).
- Figure 6a shows one example of visual interpretation of different beta-thalassemia genotypes.
- Figure 6b shows testing results on various clinical samples using the beta-thalassemia cassette, indicating that the present invention can successfully identify the genotypes of beta-thalassemia in human samples.
- Primer Sequences (Accession # AF007546.1 ):
- HBB2-B 1 Sense Amine GCATCTGACTCCTGAGGA 212
- HBB2-B2 Anti-sense Amine ACTTCTCCTCGAGTCAGAT 214
- HBB2-B3 Anti-sense Amine CAGGGCCTCACCACCA 215
- HBB2-C1 Sense Amine AGGAGAAGTCTGCCGTTACT 218
- HBB2-D2 Sense Amine CCGTTACTGCCCTGTAGG 224
- HBB2-D4 Anti-sense Amine TGTGGGGCTAGGTGAACG 226
- HBB2-E1 Anti-sense Amine TGATACCAACCTGCCCAG 228
- HBB2-E3 Sense Amine CCCTGGGCAGTTTGGTATC 230
- HBB2-F1 Sense Amine GGTGCCTTTAGTGATGGC 233
- HBB2-F2 Sense Amine TCGGTGCCTTTAAGTGATG 234
- HBB2-F3 Sense Amine TGGGTTAAGGCAATAGCAATAT 235
- HBB2-F4 Anti-sense Amine ATATTGCTATTACCTTAACCC 236
- HBB2-G 1 Sense Amine CATACCTCTTATCTTCCTCC 237
- Step 1 Denature 94°C 9 min
- Step 2 Denature 94°C 1 min
- Step 5 Go to step 2 for 39 cycles
- Beta globin mutation
- the present invention also provides a method for detecting the presence of HBV, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:241 -244, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:245-260, wherein the resulting hybridization profile would indicate the presence of HBV.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
- a universal probe of SEQ ID NO.: 257 is included for capturing nucleic acids of HBV of various genotypes.
- FIG 7 shows one embodiment of a HBV test kit detecting the presence of 8 HBV genotypes (HBV A, B, C, D, E, F, G and H).
- Figure 8 shows one example of visual interpretation of different HBV genotypes.
- this invention provides method to detect the presence of pathogens related to sexually transmitted disease (STD) including, but not limited to, protozoa, bacteria and viruses.
- STD related pathogens present in urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCytTM and SurePathTM) are detected.
- Amplification Control (AC) is included for detection of human DNA materials.
- DNA hybridization and amplification of target DNA by PCR technologies enable a faster, more sensitive and specific detection of STDs in urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCytTM and SurePathTM).
- the method can detect the presence of 12 common pathogens including 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ). These pathogens are related to cervicitis, urethritis, trichomoniasis and pelvic inflammatory disease.
- universal primer(s) and/or amplification control is included in the test.
- the present invention also provides a method for detecting the presence of sexually transmitted diseases causing pathogens in a subject, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:263-286, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:287-298, wherein the resulting hybridization profile would indicate the presence of nucleic acid fragments originated from pathogens that may develop into disease, namely sexually transmitted diseases.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
- the PCR reaction was carried out in a single tube but is in fact a two-step PCR where the pathogen-specific primer bind to target molecules by its gene-specific 3' region to generate the initial amplicons containing Universal sequence at the end. These amplicons serve as templates for the second set of primers (the Universal primers) to start the main portion of amplification and generate signal-containing amplicons, which are finally detected through subsequent hybridization.
- the Universal primers One embodiment of the amplification scheme is shown in Figure 2.
- the present method gives more accurate and sensitive detection in comparison with other commercially available STD testing kits.
- the present invention can detect STD-causing pathogens with a copy number as low as 50-300, while the kit from another manufactory can only detect STD-causing pathogens with a copy number of at least 500.
- the present invention is able to detect pathogens of low abundance in samples.
- Figure 9b shows a side-by-side comparison of performance of the present invention and a commercially available STD testing kit. Inconsistent results are observed in the four tests and the actual genotypes are confirmed by quantitative PCR (qPCR). After confirming the genotypes of pathogens using qPCR, it is found that the present invention (Test 3 and 4) has less false result than the other kit (Test 1 and 2). In addition, the present invention can detect 5 more pathogens (as noted in Figure 9b), hence detects 12 pathogens simultaneously which is the highest number as compared to those available in the market.
- qPCR quantitative PCR
- HPV 6/1 1 human papillomavirus
- Coverage of human papillomavirus (HPV) type 6 and 1 1 (HPV 6/1 1 ) in the present invention is very useful because of the high incidence of infection of HPV6 and HPV 1 1 .
- HPV6 and HPV 1 1 are found causing 90% of the cases of Genital wart, which is a highly contagious sexually transmitted disease.
- Figure 10a shows one embodiment of a STD array that can detect the presence of 12 common pathogens: 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ). Amplification control (AC) is included to check for validity of the results.
- Figure 10b shows one example of visual interpretation of the STD array.
- protozoan, bacterium and virus are detected separately.
- protozoan, bacterium and virus are detected simultaneously (Multiple infections).
- pathogen Treponema pallidum is provided as a positive template in a positive control (PC) for monitoring the performance of PCR reagents. If a TP signal does not appear in a positive control (PC) test, it may be because the DNA has been degraded during long storage or nuclease contamination. However, if the test sample produces positive signal for any of the pathogens, the test is still valid. In the positive control (PC) test, since the positive control sample only contains the DNA of Treponema pallidum (TP) but no endogenous human genomic DNA, an absence of AC signal will be resulted. A presence of an AC signal in the positive control (PC) test indicates the control test is invalid, which may be due to contamination and the test should be repeated.
- PC positive control
- test sample indicates an insufficient amount of DNA added or absence of specimen DNA in the test sample. However, if the test sample produces positive signal for any of the pathogens, the test is still valid. An AC signal may be absent in some samples due to competition from other pathogenic DNA. In this case, the test would still be valid as long as one or more positive signal(s) is detected on the array.
- the array cassette to be used in the flow-through process and/or device is of different forms and sizes. Instead of using the 10 dots array, a 35 dot is readily available whereas addition of dot can be used for detecting extra pathogens subtypes and/or more drug resistant strains caused by, for example, gene mutation. Signal can also be digitized using imaging system accompanying the hybridization device such as FT-Pro. In another embodiment, the hybridization device available is an auto-device with all analysis build-in with digitizing capability.
- the present invention is advantageous over existing testing methods and kits because it can amplify multiple targets quantitatively and detect multiple targets simultaneously with high sensitivity, and covers 12 types of STD-causing pathogens including HPV subtypes which are excluded in most of the existing kits. Coupling with the flow-through hybridization process, the present invention allows a rapid, sensitive and high throughput detection of the STD-causing pathogens.
- HSV1/2 HSV_Pr1 (minus strand) CTTGTCGATCACCTCCTCG Amine 295
- HPV6 HPV6JN2 TTATGTGCATCCGTAACTA Amine 296
- HPV11 hPV11_Pr (minus strand) GTAGCAGATTTAGACACAGATG Amine 297
- the present invention also provides a method for detecting mutations related to thrombophilia, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:299-306, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:307-3 14, wherein the resulting hybridization profile would indicate the presence of mutations related to thrombophilia.
- the primers comprise a signal generating label.
- hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
- the above method can detect mutation at a gene selected from the group consisting of Factor V Leiden, Factor II (Prothrombin), and Methylenetetrahydrofolate Reductase.
- Figure 1 1 shows one embodiment of a Thrombophilia array.
- Figure 12 shows one example of visual interpretation of the Thrombophilia array.
- Primer sequences Primer Probe sequence (5'-3') 5' Modification SEQ ID NO:
- Enzyme Conjugation Enzyme Conjugate 500 ⁇ 5 mins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Physiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides methods, primers, probes, and kits for genotyping various mutations or disease-causing agents. The present invention is applied to detect the presence of multidrug-resistant Mycobacterium tuberculosis, HBV, β-globin mutations, mutations related to thrombophilia, or the presence of sexually transmitted diseases causing agents or pathogens in a subject.
Description
RAPID GENOTYPING ANALYSIS AND KITS THEREOF
CROSS-REFERENCE TO RELATED APPLICATION
[00011 This application claims priority of U.S. Serial No. 61/791 ,933, filed March 15, 2013. The content of the preceding application is hereby incorporated in its entirety by reference into this application.
FIELD OF INVENTION
[0002] The present invention is related to the field of identification of various genotypes associated with human diseases.
BACKGROUND OF THE INVENTION
[0003] The present invention is related to identification of various genotypes. Various techniques such as sequence-specific primers polymerase chain reaction (SSP-PCR), DNA sequencing, DNA fingerprinting and single nucleotide polymorphism (SNP) genotyping have been employed for genotyping (PCT Application Publication WO/201 1 / 1 39750). Among these techniques, single nucleotide polymorphism (SNP) genotyping is more advantageous for its higher discrimination power. However, most genotyping assays involve hybridization processes of DNA which require high running cost and hand-on time. Therefore, there is a need to develop more effective genotyping assays which are faster, cheaper andable to cover more genotypes.
Tubuculosis Detection
[0004] Tuberculosis (TB) is caused by Mycobacterium tuberculosis (MTB). The emergence of anti-tuberculosis drug resistance is a serious problem for TB control programs in industrialized and developing countries alike. In addition to its clinical and epidemiological importance, multidrug-resistant tuberculosis (DR-MTB) has important economic impact because the cost of treatment is higher than that of normal MTB. DR-MTB is defined as resistance to at least two of the most effective first-line drugs, rifampin (RIF) and isoniazid (INH). These cases are on the rise globally, resulting in significant morbidity and mortality. Resistance to first-line anti-tuberculosis drugs has been linked to mutations in several genes in the MTB genome: rpoB for RIF resistance; katG and inn A for INH resistance.
[0005] Several technologies exist for DR-MTB detection. Conventional phenotypic Drug susceptibility testing (DST) remains the gold standard for MTB drug resistance testing but can
take up to eight weeks to complete. Mycobacterium tuberculosis is a slow-growing bacterium. It divides every 15-20 hours and it takes from 4 to 6 weeks to grow the colonies depending on the medium used. After that, when MTB culture is identified, drug susceptibility test will be performed which usually takes 2 additional weeks. The test hence requires a long hand-on time and leads to delay treatment of the disease if therapy starts after diagnosis is completed. Therefore, the usual practice is to begin the treatment before the results are confirmed. Alternative culture medium has been developed to shorten the time required for the test; however, some of the specimen types of MTB cannot be used on this culture medium. Conventional DNA sequencing for detection of MTB drug resistance mutations is not routinely available in the commercial setting because of the expense, necessary expertise and time-consuming nature. There are kits available in the market using different technologies including real time PCR and conventional hybridization for detecting single type of MTB or multi-drug resistant MTB. Particularly for real time PCR, due to the limited number of channels available, it is usually difficult to design assays for simultaneous detection of multidrug resistant MTB. Conventional hybridization is applicable for detecting multidrug resistant MTB; however, it usually involves long incubation time (at least 4 hours) to perform the assay. Alternatively, by utilizing polymerase chain reaction (PCR) and "Flow-through" hybridization technology, the present invention provides an array test that can simultaneously detect single-drug and multi-drug resistant types of MTB in one platform with a much shorter detection time (-35 min) than the conventional hybridization. The whole test would need less than 4 hours, from DNA extraction from samples to analysis, and gives highly specific and sensitive results.
Beta Thalassemia Detection
[0006] Beta Thalassemia is a common hemoglobinopathy that is caused by autosomal mutations, which can be sub-divided into categories depending on the extent to which beta-globin production is affected. Some mutations result in mild reductions in the production of beta-globin (denoted as β+), whereas some cause absolute silencing of the beta-globin gene, or the production of non-functional beta-globin (denoted as β°). It is estimated that around 1 .5% of the world's population are beta-thalassemia heterozygotes, or carriers, and the coupling of two carriers may produce offsprings that are homozygous for the disease. Disease severity manifests in three different degrees: from mild (thalassemia minor, β+/β or β°/β) to intermediary (thalassemia intermedia, β+/β or β°/β to severe (thalassemia major, β+/β+, β°/β+ or β°/β°). Individuals that inherit the thalassemia major trait develop hypochromic anemia, and may require life-long blood transfusion. The best method of beta-thalassemia control is prevention of birth of thalassemic children, by genetic counseling of prospective parents and prenatal diagnosis,
which have proven to be the most effective management for the disease. Beta-thalassemia is endemic in temperate regions such as Mediterranean countries, Middle East and Southeast Asia. The molecular bases for beta-thalassemia has been extensively studied and micro-mapped to point mutations along the beta-globin gene. Different geographic regions have different mutation spectra, and the frequency of mutations is not homogeneous in each region.
[0007] Current detection technologies include microarray, Allele-specific PCR (AS-PCR) and direct sequencing. Microarray can detect multiple targets simultaneously on a DNA chip and hence applicable for detecting multiple samples simultaneously. However, its application is limited for its high cost, and the result cannot be observed by naked eyes but has to be processed and interpreted using high performance scanner and sophisticated analysis software. Allele-specific PCR is a PCR technology using allele-specific primer to detect polymorphism or mutation in which only the perfectly matched oligonucleotide is able to act as a primer for amplification. The limitation of this technology is the limited throughput in one reaction. For direct sequencing, which is based on the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication, has a low efficiency in detection because of its low throughput and long hand-on time. Alternatively, the present invention provides a DNA testing using a combination of PCR and reverse dot blot hybridization which offers a highly sensitive and specific detection of beta-globin gene mutation, assisting diagnosis of beta-thalassemia.
Hepatitis B Virus Detection
[0008] HBV is the smallest DNA virus comprising 3000 nucleotides surrounded by a protein capsid. It can be transmitted through contact with blood or body fluids of an infected individual. Approximately 2 billion people are infected with HBV; in which over 350 million become HBV carriers. About one-fifth would develop HBV-related cirrhosis or eventually liver cancer. Detection of HBV can be diagnosed by surface antigen using simple blood tests and HBV DNA measurement using polymerase chain reaction (PCR). In addition, analysis of the divergence of HBV genome sequences has led to the identification of 10 HBV genotypes (A to J) and several subtypes. HBV genotypes and subtypes show a distinct geographical distribution. It has been discovered that pathogenic and therapeutic differences exist among various HBV genotypes. The determination of HBV genotypes can provide information for the management of chronic HBV infection and pre-treatment evaluation. DNA sequencing has been considered as the gold standard method for the detection of HBV genotypes. However, it is less efficient in detecting mixed genotypes. Alternatively, using molecular DNA techniques has offered a highly sensitive
and specific method for HBV genotype detection.
Detection of Sexually Transmitted Disease
[0009] Sexually transmitted diseases (STDs) are common world-wide problems. According to 2005 WHO estimates, 448 million new cases of curable STDs (syphilis, gonorrhoea, chlamydia and trichomoniasis) occur annually throughout the world in adults aged 15-49 years. In Hong Kong, around 1 in 550 was diagnosed with Sexually Transmitted diseases (not including HIV) in 2010. For pregnant woman, STDs can infect her baby before, during, or after the baby's birth. Untreated gomorrhea and chlamydia may result in infertility. Therefore, pre-married couples and pre-pregnancy women are also potential users of STDs detection. In addition, China is also a potential market of STDs diagnosis, as the number of STDs patient increase dramatically in past 20 years. The fast, low-price and accurate STDs diagnostic kit is necessary for controlling STDs in China. Current STD testing kits on the market are for detecting single parameter or multiplex of 3-4 parameters, and usually miss out human papillomavirus (HPV). Regarding the increased prevalence of STDs, screening assays that can simultaneously detect a plurality of STD-causing pathogens are highly desirable.
Thrombophilia Identification
[0010] Thrombophilia is an abnormality of blood coagulation that increases the risk of thrombosis. Studies report that about 40% of thrombophilia cases presenting with thrombosis are inherited and has been shown to be a risk factor for cardiovascular disease including venous thrombosis as well as reproductive disorders including recurrent miscarriage. There is a growing view that inherited thrombophilia would predispose women towards adverse pregnancy outcomes including recurrent pregnancy losses, intrauterine fetal death, intrauterine growth retardation, preeclampsia and placental abruption.
[0011] Over the past two decades, several gene variants have been identified for inherited thrombophilia. The top 4 mutations are located at Factor V Leiden (FVL) [ 1691 G>A], Factor II (Prothrombin) [20210OA], ethylenetetrahydrofolate Reductase (MTHFR) [677C>T] and Methylenetetrahydrofolate Reductase (MTHFR) [ 1298A>C]. Testing for these genetic variations can greatly contribute to identification of high risk population of venous thrombosis and recurrent miscarriage, so as to help lowering the individual's risk and preventing the diseases and also providing prophylactic treatment guidance.
SUMMARY OF THE INVENTION
SNP genotyping as a diagnostic tool
[0012] Other than DNA fingerprinting, SNP genotyping can be utilized for identification of gene fragments, or polymorphism of genes that have altered or attenuated the function of the gene in question. The present invention provide methods and kits for rapid, definitive identification of infectious agents, inherited disease caused by the specific DNA sequences, or the presence or absence of such infectious agents or DNA sequences that cause inherited diseases.
[0013] As discussed above, commercially available hybridization format requires high resolution image analyzer for analysis. The membrane-based micro-array Allelic-Specific-Oligonucleotide Reversed-Dot-Blotting (ASO-RDB) flow-through hybridization format (e.g., as in U.S. Patent No. 5,741 ,647) may be used to facilitate SNP genotyping. Micro-array hybridization format produces visible dots which can be analyzed by visual inspection and/or by using a less costly image analyzer. Flow-through hybridization
[0014] DNA hybridization has been the most essential method for research in modern biological science involving the molecular studies of genes. The complexity of nucleic acid sequences of various genomes were revealed by solution hybridization through the annealing process of the complementarity of specific DNA sequences. In brief, the DNA in question is amplified or digested, and allowed to hybridize with complementary DNA probes on a solid support such as a nitrocellulose membrane. However, conventional immobilization and hybridization techniques are in principle limited by the area of the membrane, and usually involve long incubation time.
[0101] Alternatively, flow-through hybridization methods and devices which can accurately control the hybridization conditions have been developed. The flow-through DNA hybridization method and device reduce hybridization time from many hours or days to minutes (the whole hybridization assay can be completed in 5-30 m inutes depending the method used to generate detection signal). The device is also inexpensive to manufacture, and uses 10 times less reagents than conventional hybridization devices which will lead to more affordable DNA diagnosis technology. Flow-through hybridization technology also gives more sensitive and accurate results of detection/identification, and can be universally applied to various techniques such as conventional Southern, Northern, Dot-Blot, Slot-Blot and Reversed-Dot Blot hybridization. Because of its higher efficiency, accuracy and sensitivity, flow-through hybridization is more advantageous in comparison to conventional hybridization techniques.
[0102] PCT application WO/201 1 / 139750 describes multiple lateral flow-through detection devices connected to a central control unit. The hybridization device comprises a central controlling unit connected to one or more lateral flow device. The central controlling unit provides power to and controls the lateral flow device where the hybridization process and developing procedures are carried out. Several reactions (or several samples and/or analytes) can be tested simultaneously in a single lateral flow device or in several devices (controlled individually at different conditions) at the same time. The lateral flow device can be in a format of 'n x m' dot matrix (array) or in the form of linear arrays. More descriptions on methods and devices for performing flow-through hybridization can be found in the U.S. Patent No. 5,741 ,647, U.S. Patent No. 6,020, 1 87 and PCT application WO/201 1/ 139750. One of ordinary skill in the art would be able to use flow-through hybridization as similar to those described in the U.S. Patent No. 5,741 ,547 or 6,020, 187, or any new embodiments capable of carrying out flow-through hybridization for rapid detection of infectious agents, inherited disease caused by the specific DNA sequences, or the presence or absence of such infectious agents or DNA sequences that cause inherited diseases. Signal detection can be digitized using the imaging system accompanying the hybridization device, such as FT-Pro. The hybridization device to be used in the present invention can be auto-device with all analysis build-in with digitizing capability. Multidrug-Resistance Tuberculosis Detection
[0015] This invention provides method and kit to detect rifampicin (RIF) and isoniazid (INH) resistant strains of Mycobacteriu Tuberculosis (MTB) using Polymerase Chain Reaction (PCR) and "Flow-through" hybridization technology. Mutation of the MTB gene encoding beta subunit of RNA polymerase (rpoB) is found associated with rifampin resistance, while mutation in genes katG and InhA, which respectively encode for catalase peroxidase and enoyl-ACP-reductase, are reported to be associated with isoniazid resistance. In the present invention, primers specific to rpoB, katG and InhA are used to amplify corresponding genes, and they have been verified not cross-reacting with human genome. Primer RS-IAC, which does not target at any human or MTB genome, serves as an internal amplification control for monitoring the PCR amplification process. Ten mutation DNA probes are included for detection of drug resistant mutations in rpoB (D516V, D516G, H526D, H526Y, H526L 1 , S53 1 L and S53 1 W), katG (S3 15T 1 and S315T2), and inhA (-15TC/T). Five wild-type MTB DNA probes are also included for detection of wild-type MTB variants, which helps to validate if the PCR reaction and amplification of rpoB, katG and inhA genes have been successfully performed. The primers can be biotinylated for hybridization.
Beta Thalassemia Detection
[0016] This invention provides method and kit for the detection of beta-globin mutations including TATA -28 (A>G), TATA -29 (A>G), Initiation Codon (G>A), Codon 5 (-CT), Codons 8/9 (+G), Codon 15 (G>A), Codon 16 (-C), Codon 17 (A>T), Codon 19 (A>G), Codon 26 (G>A) (Hb E), Codons 27/28 (+C), Codon 30 G>C, IVS 1 .1 (G>T), 1VS 1.1 (G>A), 1VS 1.5 (G>C), Codons 41/42 (-TCTT), Codon 43 (G>T), Codons 71/72 (+A), IVS2.1 (G>A), IVS2.654 (OT), and 619 bp deletion.
Hepatitis B Virus detection
[0017] This invention provides method and kit to detect the presence of 8 HBV genotypes (HBV Genotypes A, B, C, D, E, F, G and H) in human serum samples.
Detection of Sexually Transmitted Disease
[0018] This invention provides method and kit to detect the presence of protozoa, bacteria and viruses in various specimens such as urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCyt™ and SurePath™). Amplification Control (AC) is included for detection of human DNA materials to check for the presence of sufficient cellular content and validity of the results. AC can be used to monitor the presence of PCR inhibitors and the presence of sufficient amount of extracted DNA during PCR amplification. Absence of Amplification Control signal may indicate either failure of the PCR amplification (PCR inhibitor present) or insufficient amount of DNA (or absence of specimen) during PCR amplification. Positive Control (PC) which contains a positive template is also included to monitor the performance of PCR reagents. [0019] DNA hybridization and PCR technologies enable a faster detection of STD-causing pathogens in urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCyt™ and SurePath™). In one embodiment, the method and kit can detect the presence of 12 common pathogens: 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genital ium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ). These pathogens are related to cervicitis, urethritis, trichomoniasis and pelvic inflammatory disease.
[0020] The present invention provides universal primers and pathogen-specific primers for detecting STD-causing pathogens. Universal primers are used to achieve a balanced
amplification among different targets in the multiplex PCR. Sequences were tested by PCR and gel electrophoresis on their specificity on pathogen targets and human DNA to prove that they do not cross-react with other pathogens and human genome. Two universal sequences that do not cross-react with the pathogen targets and human DNA were designed and added to the 5 'end of pathogen specific primers. The same was done to the AC specific primers. The resulting universal primers and pathogen-specific primers tagged with the universal sequences were further tested by PCR and gel electrophoresis and proven not cross-reacting with other pathogens and human genome (Figure 1 ). In one embodiment, pathogen-specific primers tagged with universal sequences and two universal primers were included in a single PCR. In the first round of PCR, pathogen-specific primers bind to their specific target and create a PCR product carrying the universal sequence. Next in the second round of PCR, the universal primers bind to the universal-sequence-tagged PCR products (Figure 2). Under an optimized PCR condition, we can achieve a balanced amplification and avoid the loss of amplification due to different amplification efficiencies of different pathogen targets. It also ensures only pathogen-specific amplicons would be generated using the universal primers, leading to a more accurate detection by the DNA probes. The universal primers system described herein can be also applied to other methods and kits detecting nucleic acids or gene associated with DR-MTB, Beta-globin, HBV and thrombophilia, and also other diseases or conditions that are not described in the present invention.
Thrombophilia Identification
[0021] This invention provides method for the identification of gene variants related to inherited thrombophillia, including Factor V Leiden (FVL) [ 1691 G>A], Factor II (Prothrombin)
[20210OA], Methylenetetrahydrofolate Reductase (MTHFR) [6770T] and Methylenetetrahydrofolate Reductase (MTHFR) [ 1298A>C] .
[0022] Although PCR was used for amplification in the data validating examples, any method that can produce specific target sequence(s) in sufficient quantity for the identification and flow-through hybridization analysis may be used. Amplification may not be necessary if sufficient quantity of the target sequence(s) can be obtained for the identification and analysis. Detection can be accomplished by labeling of the target DNA or conjugates.
DETAILED DESCRIPTION OF THE DRAWINGS
[0023] Figure la shows an electrophoretic image of PCR reactions on human clinical samples using universal primers (SEQ ID NO. 285 and 286). Specific bands are only observed in positive
samples in which the pathogens are present (i.e. CT-positive, NG-positive, HPV-6 and HPV-11 positive), indicating that the universal primers do not cross react with human DNA. Figure lb shows an electrophoretic image of PCR reactions on human clinical samples using pathogen-specific primers (SEQ ID NO. 263-282) and universal primers (SEQ ID NO. 285 and 286). Specific bands are observed in each sample in which the corresponding pathogens are present, indicating that the primers are highly specific to their respective pathogens. Similar observation can be found in both monoplex and multiplex PCR reactions.
[0024] Figure 2 shows one embodiment of a PCR amplification scheme using Universal primers and gene-specific primers in one single reaction.
[0025] Figure 3 shows one embodiment of DR-MTB cassette (left panel) and signal position (right panel) (grids shown for illustration purpose only) for DR-MTB detection. IAC is the internal amplification control for monitoring PCR Amplification process. HC is the hybridization control which monitors the hybridization process. Validity of PCR amplification and specimen are also accessed by various controls.
[0026] Figure 4 shows one example of visual interpretation of different MTB mutants. [0027] Figure 5 shows one embodiment of beta-thalassemia cassette and signal position (grids shown for illustration purpose only).
[0028] Figure 6a shows one example of visual interpretation of different beta-thalassemia genotypes. Figure 6b shows testing results on various clinical samples using the beta-thalassemia cassette.
[0029] Figure 7 shows one embodiment of a HBV test kit detecting the presence of 8 HBV genotypes (HBV A, B, C, D, E, F, G and H). Universal primer, IAC and HC are also included. [0030] Figure 8 shows one example of visual interpretation of different HBV genotypes.
[0031] Figure 9a shows a comparison of sensitivity of the present invention and a STD testing kit from other manufactory. Figure 9b shows a side-by-side comparison of performance of the present invention and an STD testing kit from other manufactory on clinical samples.
[0032] Figure 10a shows one embodiment of a STD array, cassette format and signal position. The array can detect the presence of 12 common pathogens: 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ). Amplification Control (AC) is used to monitor the presence of PCR inhibitors and the presence of sufficient amount of extracted DNA during PCR amplification. Absence of Amplification Control signal indicates either failure of the PCR amplification (PCR inhibitor present) or insufficient amount of DNA (or absence of specimen) during PCR amplification. Treponema pallidum (TP) can be provided as a positive control (PC) which contains a positive template to monitor the performance of PCR reagents. Figure 10b shows one example of visual interpretation of the STD array.
[0033] Figure 11 shows one embodiment of a Thrombophilia array.
[0034] Figure 12 shows one example of visual interpretation of the Thrombophilia array.
DETAILED DESCRIPTION OF THE INVENTION
[0035] The following terms shall be used to describe the present invention. In the absence of a specific definition set forth herein, the terms used to describe the present invention shall be given their common meaning as understood by those of ordinary skill in the art.
[0036] As used herein, the expression "Allelic-Specific-Oligonucleotide Reversed-Dot-Blotting (ASO-RDB)" refers to assays using Allelic-Specific-Oligonucleotide probes immobilized on a solid matrix capable of capturing target molecules for detection through hybridization processes.
[0037] As used herein, the term "flow-through hybridization" refers to the hybridization process utilizing the technology described in U.S. Patent No. 5,741 ,647. [0038] As used herein, the term "flow-through hybridization device" or "flow-through device" refers to the device depicted in U.S. Patent No. 6,020, 187 and/or the lateral flow device depicted in PCT application WO/201 1 /139750 or any flow-through device designed subsequently.
Detection of pathogens and DNA targets
[0103] The present invention provides methods, primers, probes and kits for identification and/or
W detection of various nucleic acids, mutations, agents, pathogens and/or diseases. In one embodiment, the present invention is applied to detecting the presence of Tuberculosis, HBV, HCV, SARS, respiratory infectious viruses, sexually-transmitted diseases-causing agents, beta-globin, thrombophilia and/or the nucleic acids associated thereof, individually or in combinations. The method involves PCR amplification using specific primers to generate amplicons, hybridizing said amplicons with oligonucleotide probes. The resulting hybridization profile would indicate the presence of the nucleic acids, mutations, agents, pathogens and/or diseases in question. [0104] In one embodiment, the hybridization of the amplicons with oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process. In one embodiment, the oligonucleotide probes are immobilized for hybridization. In one embodiment of a flow-through process, the sensitivity of the hybridization depends on the ratio of the area comprising the probes to the total area of the membrane of the array. In one embodiment of a lateral flow-through process, the sensitivity of the hybridization depends on the ratio of the cross-sectional area comprising the probes to the total cross-sectional area of the membrane across the flow direction.
[0105] In one embodiment, the present invention provides a method for detecting the presence of nucleic acid and/or exogenous agent in a subject, comprising the steps of: (a) amplifying a template nucleic acid from a sample obtained from the subject with primers selected from SEQ ID NOs: 174-181 , 201 -205, 241 -244, 263-286 and 299-306 to generate amplicons, alone or in combination thereof; and (b) hybridizing said amplicons with oligonucleotide probes selected from SEQ ID NOs: 182-200, 206-240, 245-260, 287-298, and 307-314, alone or in combination thereof wherein the resulting hybridization profile would indicate the presence of nucleic acid and/or exogenous agent in said subject. In one embodiment, the number of primers selected is 2-49 and the number of probes selected is 2-92. In another embodiment, the number of primers selected is 2-24 and the number of probes selected is 2-35. [0106] In another embodiment, the present invention provides a method for detecting the presence of nucleic acid and/or exogenous agent in a subject, comprising the steps of: (a) amplifying a template nucleic acid from a sample obtained from the subject with primers selected from SEQ ID NOs: 174-181 , 201 -205, 241 -244, 263-286 and 299-306 to generate sufficient amplicons, alone or in combination thereof; and (b) hybridizing said amplicons with oligonucleotide probes selected from SEQ ID NOs: 182-200, 206-240, 245-260, 287-298, and
307-314, alone or in combination thereof wherein the resulting hybridization profile would indicate the presence of nucleic acid and/or exogenous agent in said subject.
[0107] In one embodiment, the present invention provides a method for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs: 174- 181 , thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs: 182-200, wherein the resulting hybridization profile would indicate the presence of multidrug-resistant Mycobacterium tuberculosis or nucleic acid of DR-MTB. In another embodiment, the method for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB comprises the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs: 174-181 , thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs: 182-200, wherein the resulting hybridization profile would indicate the presence of multidrug-resistant Mycobacterium tuberculosis or nucleic acid of DR-MTB. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
[0108] In one embodiment, the above methods can detect the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB having one or more of the following mutations: one of seven mutations in the rpoB gene; one of two mutations in the katG gene; and one mutation in the inhA gene. The present invention also provides a kit for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB, comprising primers selected from the group consisting of SEQ ID NOs: 174-181 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 1 82-200. In one embodiment, the kit for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), or nucleic acid of DR-MTB, comprises primers of SEQ ID NOs: 174- 181 and oligonucleotide probes of SEQ ID NOs: 182-200.
[0109] The present invention also provides a method of detecting beta-globin mutations in a subject having beta-thalassemia, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers
selected from the group consisting of SEQ ID NOs:201 -205, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:206-240, wherein the resulting hybridization profile would indicate the genotypes of beta-thalassemia. In one embodiment, the method of detecting beta-globin mutations in a subject having beta-thalassemia comprises the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:201 -205, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:206-240, wherein the resulting hybridization profile would indicate the genotypes of beta-thalassemia. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process and/or related devices. In one embodiment, the above method of detecting beta-globin mutations can detect one of twenty one beta-globin mutations. [0110] The present invention also provides a kit for detecting beta-globin mutations, comprising primers selected from the group consisting of SEQ ID NOs:201 -205 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 206-240. In one embodiment, the kit for detecting beta-globin mutations comprises primers of SEQ ID NOs:201 -205 and oligonucleotide probes of SEQ ID NOs: 206-240.
[0111] The present invention also provides a method for detecting the presence of HBV, or nucleic acid of HBV, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:241 -244, thereby generating HBV amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:245-260, wherein the resulting hybridization profile would indicate the presence of HBV or nucleic acid of HBV. In one embodiment, the method for detecting the presence of HBV, or nucleic acid of HBV comprises the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:241 -244, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:245-260, wherein the resulting hybridization profile would indicate the presence of HBV or nucleic acid of HBV. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
[0112] In one embodiment, the above method can detect the presence of HBV or nucleic acid of HBV, having a genotype selected from the group consisting of HBV genotypes A to H. The present invention also provides a kit for detecting the presence of HBV or nucleic acid of HBV, comprising primers selected from the group consisting of SEQ ID NOs:241 -244 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 245-260. In one embodiment, the kit for detecting the presence of HBV or nucleic acid of HBV comprises primers of SEQ ID NOs:241 -244 and oligonucleotide probes of SEQ ID NOs: 245-260. [0113] The present invention also provides a method for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:263-286, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:287-298, wherein the resulting hybridization profile would indicate the presence of nucleic acid originated from pathogens that may develop into disease, namely sexually transmitted diseases. In one embodiment, the present invention provides a method for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:263-286, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:287-298, wherein the resulting hybridization profile would indicate the presence of nucleic acid originated from pathogens that may develop into disease, namely sexually transmitted diseases. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices. [0114] In one embodiment, the method for detecting the presence of sexually transmitted diseases causing pathogens can detect the presence of sexually transmitted diseases caused by an organism selected from the group consisting of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum, Herpes simplex virus 1 , Herpes simplex virus 2, Human papillomavirus type 6, and Human papillomavirus type 1 1 . The present invention also
provides a kit for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject, comprising primers selected from the group consisting of SEQ ID NOs:263-286 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 287-298. In one embodiment, the kit for detecting the presence of sexually transmitted diseases causing pathogens, or nucleic acid of said pathogens in a subject comprises primers of SEQ ID NOs:263-286 and oligonucleotide probes of SEQ ID NOs: 287-298.
[0115] The present invention also provides a method for detecting mutations related to thrombophilia, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:299-306, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:307-314, wherein the resulting hybridization profile would indicate the presence of mutations related to thrombophilia. In one embodiment, the primers comprise a signal generating label. In another embodiment, the method for detecting mutations related to thrombophilia comprises the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers of SEQ ID NOs:299-306, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:307-3 14, wherein the resulting hybridization profile would indicate the presence of mutations related to thrombophilia. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices. [0116] In one embodiment, the method for detecting mutations related to thrombophilia can detect mutation at a gene selected from the group consisting of Factor V Leiden, Factor II (Prothrombin), and Methylenetetrahydrofolate Reductase. The present invention also provides a kit for detecting the presence of mutations related to thrombophilia, comprising primers selected from the group consisting of SEQ ID NOs:299-306 and oligonucleotide probes selected from the group consisting of SEQ ID NOs: 307-3 14. In one embodiment, the kit for detecting the presence of mutations related to thrombophilia comprises primers of SEQ ID NOs:299-306 and oligonucleotide probes of SEQ ID NOs: 307-314.
[0117] The invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed
are only illustrative, and are not meant to limit the invention as described herein, which is defined by the claims which follow thereafter.
[0118] Throughout this application, various references or publications are cited. Disclosures of these references or publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. It is to be noted that the transitional term "comprising", which is synonymous with "including", "containing" or "characterized by", is inclusive or open-ended and does not exclude additional, un-recited elements or method steps.
EXAMPLE 1
Test Procedures
[0119] Procedures for isolation of DNA, PCR amplification, hybridization, detection of target and result analysis as described in WO/201 1 /139750 or relevant procedures and techniques that are known to one skilled in the art can be applied to the present invention. Various internal controls (IC) can be included in the test assay to validate the DNA samples, PCR amplification and color development. Various flow-through membrane array size and format can be used for according to individual need, or for optimizing the usage of the reaction chamber to achieve maximized cost saving.
EXAMPLE 2
Genotyping For Multidrug-Resistant Tuberculosis [0120] In one embodiment, the present invention provides methods and array test kits for DR-MTB genotyping. The methods and kits are designed to detect rifampicin (RIF) and isoniazid (INH) resistant strains of Mycobacterium Tuberculosis (MTB) using Polymerase Chain Reaction (PCR) and "Flow-through" hybridization technology. Primers specific to rpoB, katG and InhA are used to amplify corresponding genes, and they have been verified not cross-reacting with human genome. Primer RS-IAC is an internal amplification control which does not target at human or MTB genome but serves as an internal amplification control for monitoring the PCR amplification process. Ten mutation probes are included for detection of drug resistant mutations in rpoB (D516V, D516G, H526D, H526Y, H526L 1 , S53 1 L and S531 W), katG (S315T1 and S3 15T2), and inhA (- 15TC/T). Five wild-type MTB probes are also included for detection of wild-type MTB variants, which helps to validate if the PCR reaction and amplification of rpoB, katG and inhA genes have been successfully performed. In one embodiment, the primers are biotinylated for hybridization.
[0121] In one embodiment, the present invention provides a method for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (DR-MTB), comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs: 174- 18 1 , thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs: 182-200, wherein the resulting hybridization profile would indicate the presence of multidrug-resistant Mycobacterium tuberculosis. In one embodiment, the present invention can detect the presence of multidrug-resistant Mycobacterium tuberculosis having one or more of the following mutations: one of seven mutations in the rpoB gene; one of two mutations in the katG gene; and one mutation in the inhA gene. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process. [0122] Figure 3 shows one embodiment of DR-MTB cassette (left panel) and the respective positions of probes and signals (right panel). IAC is the internal amplification control for monitoring PCR amplification process. HC is the hybridization control which monitors the hybridization process. Figure 4 shows one embodiment of DR-MTB array profile for DR-MTB detection. In one embodiment, RIF and ΓΝΗ resistant strains of MTB are detected separately. In another embodiment, MTB strains resistant to both RIF and 1NH are detected (multi-drug resistant). In one embodiment, strains that are neither resistant to rifampicin (RIF) nor isoniazid (INH) are detected (out of panel mutation). Validity of PCR amplification and specimen are also accessed by various controls. Primer Sequences
Probe Sequences
Probe Probe sequence (5'-3') 5' Modification SEQ ID NO TB-DR-Rpob-CTRL GCTGGTGCCGAAGAA AMINO 1 82
MTB-DR-KatG-CTRL CGGGGTGTTCGTCCATAC AMINO 1 83
MTB-DR-inhA-CTRL GGTATGTCCACGAGCGTAAC AMINO 1 84
MTB-DR-Rpob-WTc GGTTGTTCTGGTCCATG AMINO 1 85
MTB-DR-Rpob-Wte TGACCCACAAGCGCCGA AMINO 186
MTB-DR-Rpob-Wtf GACTGTCGGCGCTGG AMINO 187
MTB-DR-KatG-WT GATGCCGCTGGTGATCG AMINO 188 TB-DR-inhA-WT AACCTATCGTCTCGCCG AMINO 1 89
MTB-DR-Rpob-MUTc l GGTTGTTCTGGACCATGA AMINO 1 90
MTB-DR-Rpob-MUTc2 GGTTGTTCTGGCCCATG AMINO 191
MTB-DR-Rpob- UTe 1 GACCGACAAGCGCCGA AMINO 192
MTB-DR-Rpob-MUTe2 GCGCTTGTAGGTCAACC AMINO 193
MTB-DR-Rpob-MUTe3 GCGCTTGAGGGTCAAC AMINO 194
MTB-DR-Rpob-MUTfl CCCCAGCGCCAACAGT AMINO 1 95 TB-DR-Rpob-MUTf2 GACTGTGGGCGCTGG AMINO 196
MTB-DR-KatG-MUTl GATGCCGGTGGTGATC AMINO 197
MTB-DR-KatG-MUT2 GATGCCTGTGGTGATCG AMINO 198
MTB-DR-inhA- UTl CAACCTATCATCTCGCCG AMINO 199
RS-IAC-P CTCGAATGCCTCGTATCAT AMINO 200
Below are some example protocols for PCR and hybridization:
EXAMPLE 3
Beta Thalassemia Genotyping
[0123] This invention provides a system for the detection of beta-globin mutations including TATA-28 (A>G), TATA-29 (A>G), Initiation Codon (G>A), Codon 5 (-CT), Codons 8/9 (+G), Codon 15 (G>A), Codon 16 (-C), Codon 17 (A>T), Codon 19 (A>G), Codon 26 (G>A) (Hb E), Codons 27/28 (+C), Codon 30 G>C, IVS l . l (G>T), IVS l . l (G>A), IVS 1 .5 (G>C), Codons 41/42 (-TCTT), Codon 43 (G>T), Codons 71/72 (+A), IVS2.1 (G>A), IVS2.654 (C>T), and 619 bp deletion.
W
[0124] The present invention also provides a method of detecting beta-globin mutations in a subject having beta-thalassemia, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:201 -205, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:206-240, wherein the resulting hybridization profile would indicate the genotypes of beta-thalassemia. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process. In one embodiment, the above method can detect one of twenty one beta-globin mutations.
[0125] Figure 5 shows one embodiment of beta-thalassemia cassette and signal position (grids shown for illustration purpose only). Figure 6a shows one example of visual interpretation of different beta-thalassemia genotypes. Figure 6b shows testing results on various clinical samples using the beta-thalassemia cassette, indicating that the present invention can successfully identify the genotypes of beta-thalassemia in human samples. Primer Sequences (Accession # AF007546.1 ):
Probe Sequences (Accession # AF007546.1 ):
HBB2-B 1 Sense Amine GCATCTGACTCCTGAGGA 212
HBB2-B la Sense Amine GCACCTGACTCCTGAGG 213
HBB2-B2 Anti-sense Amine ACTTCTCCTCGAGTCAGAT 214
HBB2-B3 Anti-sense Amine CAGGGCCTCACCACCA 215
HBB2-B4 Sense Amine GTTGGTGGTAAGGCCCT 216
HBB2-B5 Anti-sense Amine CCAGGGGCCTCACCA 217
HBB2-C1 Sense Amine AGGAGAAGTCTGCCGTTACT 218
HBB2-C2 Sense Amine AGGAGAAGGTCTGCCGTTA 219
HBB2-C3 Sense Amine GAGGTTCTTTGAGTCCTTTGG 220
HBB2-C4 Anti-sense Amine CAAAGGACTCAACCTCTGG 221
HBB2-C5 Sense Amine CCCAGAGGTTCTTTTAGTC 222
HBB2-D1 Sense Amine TGTGGGGCAAGGTGAAC 223
HBB2-D2 Sense Amine CCGTTACTGCCCTGTAGG 224
HBB2-D3 Sense Amine CTGTGGGGAAGGTGAAC 225
HBB2-D4 Anti-sense Amine TGTGGGGCTAGGTGAACG 226
HBB2-D5 Anti-sense Amine CTTCATCCACGCTCACCT 227
HBB2-E1 Anti-sense Amine TGATACCAACCTGCCCAG 228
HBB2-E2 Sense Amine CTGGGCAGATTGGTATCA 229
HBB2-E3 Sense Amine CCCTGGGCAGTTTGGTATC 230
HBB2-E4 Sense Amine GCAGGTTGCTATCAAGGTTAC 231
HBB2-E5 Anti-sense Amine ATACCAACGTGCCCAGG 232
HBB2-F1 Sense Amine GGTGCCTTTAGTGATGGC 233
HBB2-F2 Sense Amine TCGGTGCCTTTAAGTGATG 234
HBB2-F3 Sense Amine TGGGTTAAGGCAATAGCAATAT 235
HBB2-F4 Anti-sense Amine ATATTGCTATTACCTTAACCC 236
HBB2-G 1 Sense Amine CATACCTCTTATCTTCCTCC 237
HBB2-G2 Sense Amine TGTAACAAGTAGAGATTCAAGTA 238
HBB2-G3 Sense Amine GAACTTCAGGGTGAGTCTAT 239
HBB2-G4 Anti-sense Amine GAACTTCAGGATGAGTCTATG 240
Program Temperature
Step 1 Denature 94°C 9 min
Step 2 Denature 94°C 1 min
Step 3 Annealing 60°C 30 sec
Step 4 Extension 72°C 30 sec
Step 5 Go to step 2 for 39 cycles
(Total: 40 cycles)
Step 6 Final 72°C 7 min
Extension
Step 7 Final Hold 4°C forever
Step 8 End
One embodiment of hybridization protocol:
Data interpretation for Beta globin mutation:
Mutation points Genotype Type specific signal
1 Initiation codon T>G β° Α2
2 TATA -28 A->G P+ Α4
3 TATA -29 A->G f Α5
4 Codon 5-CT Β3
5 Codon 26 G->A β+ Β4
6 Codons 27/28 +C β° Β5
7 Codons 8/9 +G β° C2
8 Codons 41/42- TCTT β° C4
9 Codon 43 G>T β° C5
10 Codon 15 G>A β° D2
11 Codon 16-C β° D3
12 Codon 17 A>T β° D4
13 Codon 19 A>G β+ D5
14 IVS1.1 G>A β° E2
15 IVS1.1 G>T β° E3
16 IVS 1.5 G>C β+ E4
17 Codon 30 G>C β° E5
18 Codons 71/72 +A β° F2
19 IVS2,654 OT F4
20 619-bp deletion G2 21 1VS2.1 OA G4
EXAMPLE 4
HBV Genotyping [0126] The present invention also provides a method for detecting the presence of HBV, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:241 -244, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:245-260, wherein the resulting hybridization profile would indicate the presence of HBV. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process. In one embodiment, a universal probe of SEQ ID NO.: 257 is included for capturing nucleic acids of HBV of various genotypes.
[0127] Figure 7 shows one embodiment of a HBV test kit detecting the presence of 8 HBV genotypes (HBV A, B, C, D, E, F, G and H). Figure 8 shows one example of visual interpretation of different HBV genotypes.
Primer se uences:
Probe sequences:
IAC 1AC-R-P2 CTCGAATGCCTCGTATCAT 258 5'-Amine
HC Bio-HC GTTCCAACTAGGAACATCA 259 5 '-Amine
3'-Biotin
HC Amine-HC GTTCCAACTAGGAACATCA 260 5 '-Amine
HBV Positive Control sequence [560 bp] (cloned in vector pUC57):
TGGGATTCTATATAAGAGGGAAACTACACGTAGCGCCTCATTTTGCGGGTCACCATATT CTTGGGAACAAGAGCTACATCATGGGAGGTTGGTCATCAAAACCTCGCAAAGGCATG GGGACGAACCTTTCTGTTCCCAACCCTCTGGGATTCTTTCCCGATCATCAGTTGGACC CTGCATTCGGAGCCAATTCAAACAATCCAGATTGGGACTTCAACCCCATCAAGGACC ACTGGCCACAAGCCAACCAGGTAGGAGTGGGAGCATTCGGGCCAGGGTTCACTCCC CCACACGGAGGTGTTTTGGGGTGGAGCCCTCAGGCTCAGGGCATATTGGCCACAGTG CCAGCAGTGCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGGCAGCCTACTCCC ATCTCTCCACCTCTAAGAGACAGTCATCCTCAGGCC ATGCAGTGGAATTCCACAGCTT TCCACCAAGCTCTGCAAGATCCCAGAGTCAGGGGCCTGTATTTTCCTGCTGGTGGCTC CAGTTCAGGAACACTCAACCCTGTTCCAACTATTGCCTCTCAC (SEQ ID NO:261 )
Internal Amplification Control sequence [500 bp] (cloned in vector pUC57):
GAG ACAGGTTCGTCCAATCCCGTGCCGCGGCCTTGGCAGGGGGTTCGCAGGCCCCAC CCGAAGCGTTGCTGAAGGCTCAGGCCTCTGAGCGACAAAAGCTTTAAACGCGAGTT CCCGCCCATAACCTGGACCGAATGCGGGACCATGCATCGTTCCACTGTGTTTGTCCCA TGTAGGACGGGCGCAAGGCGTGCTTAGCTCAGCCTCGAATGCCTCGTATCATTGTGCA CCCGCCGGTCACCAGCCAACGATGTGCGGACGGCGTTGCAACTTCCGGGGCCCAAC CTGACCGTCCTGGGTACCGCACTCTGGGCAGTGCGAGGTAATGCCAGTCGCCCAGTG CCGAACAACACCTGACCTAACGGTAAGAGGCTCACATAATGGCTCCGCCGGCGCGCC CAGGGTACATTAGGTCAGCATCGGATGGACTGACATGAACCTTCACACCGAAGCGGA AACGGGTGCGTGGACCAGCGAGGAGCAAACGAAAATTCCTGGCC (SEQ ID NO:262) Below are some example protocols for PCR and hybridization:
Extension 72 30 sec
Hold Final Extension 72 5 min
Hold Final Hold 4 oo
This thermal profile is suitable for Applied Biosystems Perkin Elmer (ABI-PE) 9600, GeneAmp PCR System 9700, Veriti (Applied Biosystems), PTC-200 (MJ Research).
One embodiment of hybridization protocol :
EXAMPLE 5
Genotyping and Simultaneous Detection of Multiple Pathogens For Sexually Transmitted
Diseases
[0128] In one embodiment, this invention provides method to detect the presence of pathogens related to sexually transmitted disease (STD) including, but not limited to, protozoa, bacteria and viruses. In one embodiment, STD related pathogens present in urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCyt™ and SurePath™) are detected. In one embodiment, Amplification Control (AC) is included for
detection of human DNA materials. DNA hybridization and amplification of target DNA by PCR technologies enable a faster, more sensitive and specific detection of STDs in urine, urogential swab (urethral, vaginal, cervical and lesion) and Liquid-based cytology specimens (PreservCyt™ and SurePath™). I n one embodiment, the method can detect the presence of 12 common pathogens including 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ). These pathogens are related to cervicitis, urethritis, trichomoniasis and pelvic inflammatory disease. In another embodiment, universal primer(s) and/or amplification control is included in the test.
[0129] The present invention also provides a method for detecting the presence of sexually transmitted diseases causing pathogens in a subject, comprising the steps of: (a) obtaining from the subject a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:263-286, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:287-298, wherein the resulting hybridization profile would indicate the presence of nucleic acid fragments originated from pathogens that may develop into disease, namely sexually transmitted diseases. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process or a reversed flow-through process and/or related devices.
[0130] Below table shows the primer sequences of SEQ ID NOs.: 263-284, whereas these sequences consist of two parts: in the 5 ' portion is an artificial synthetic nucleic acid sequences not homologous to any of these target pathogens and not related to any organisms that may be found in human that may be amplified; the 3' portion of the primer consists of pathogen-specific sequence so that each can effectively bind to the nucleic acid of corresponding pathogen to generate amplicons to enable detection. This 5 ' portion of the sequence is common to all hybridprimers called Universal sequence. The art of designing such Universal sequences for use as Universal primers such as those disclosed in the present invention are selected after thorough consideration and experimentation to rule out any possibility of amplifying any organisms that may be found in the sample source, i.e. pathogens and human genomic DNA (Figure 1). Universal sequences verified to be specific are then combined with various pathogen-specific sequences to give pathogen-specific primers, which are capable of generating amplicons
containing the Universal sequences. These amplicons become new templates for the second PCR, which uses Universal primers of SEQ ID NO.: 285 and 286 to effectively amplify all different amplicons with the same efficiency, therefore linearly generating amplicons which has a final concentration directly proportional to the initial concentrations of the target DNA. This is especially crucial to samples containing multiples targets, because target at low copy number can still be amplified to achieve considerable concentration for positive detection, using Universal primers can help rectifying such error and therefore increasing sensitivity drastically. In one embodiment, the PCR reaction was carried out in a single tube but is in fact a two-step PCR where the pathogen-specific primer bind to target molecules by its gene-specific 3' region to generate the initial amplicons containing Universal sequence at the end. These amplicons serve as templates for the second set of primers (the Universal primers) to start the main portion of amplification and generate signal-containing amplicons, which are finally detected through subsequent hybridization. One embodiment of the amplification scheme is shown in Figure 2. [0131] By using the Universal primers, the present method gives more accurate and sensitive detection in comparison with other commercially available STD testing kits. As seen in Figure 9a, the present invention can detect STD-causing pathogens with a copy number as low as 50-300, while the kit from another manufactory can only detect STD-causing pathogens with a copy number of at least 500. The present invention is able to detect pathogens of low abundance in samples.
[0132] Figure 9b shows a side-by-side comparison of performance of the present invention and a commercially available STD testing kit. Inconsistent results are observed in the four tests and the actual genotypes are confirmed by quantitative PCR (qPCR). After confirming the genotypes of pathogens using qPCR, it is found that the present invention (Test 3 and 4) has less false result than the other kit (Test 1 and 2). In addition, the present invention can detect 5 more pathogens (as noted in Figure 9b), hence detects 12 pathogens simultaneously which is the highest number as compared to those available in the market. Coverage of human papillomavirus (HPV) type 6 and 1 1 (HPV 6/1 1 ) in the present invention is very useful because of the high incidence of infection of HPV6 and HPV 1 1 . HPV6 and HPV 1 1 are found causing 90% of the cases of Genital wart, which is a highly contagious sexually transmitted disease.
[0133] Figure 10a shows one embodiment of a STD array that can detect the presence of 12 common pathogens: 1 protozoan (Trichomonas vaginalis), 7 bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum,
Ureaplasma parvum, Treponema pallidum) and 4 viruses (Herpes simplex virus 1 & 2, Human papillomavirus type 6 & 1 1 ). Amplification control (AC) is included to check for validity of the results. Figure 10b shows one example of visual interpretation of the STD array. In one embodiment, protozoan, bacterium and virus are detected separately. In another embodiment, protozoan, bacterium and virus are detected simultaneously (Multiple infections).
[0134] In one embodiment, pathogen Treponema pallidum (TP) is provided as a positive template in a positive control (PC) for monitoring the performance of PCR reagents. If a TP signal does not appear in a positive control (PC) test, it may be because the DNA has been degraded during long storage or nuclease contamination. However, if the test sample produces positive signal for any of the pathogens, the test is still valid. In the positive control (PC) test, since the positive control sample only contains the DNA of Treponema pallidum (TP) but no endogenous human genomic DNA, an absence of AC signal will be resulted. A presence of an AC signal in the positive control (PC) test indicates the control test is invalid, which may be due to contamination and the test should be repeated.
[0135] An absence of the AC signal in the test sample indicates an insufficient amount of DNA added or absence of specimen DNA in the test sample. However, if the test sample produces positive signal for any of the pathogens, the test is still valid. An AC signal may be absent in some samples due to competition from other pathogenic DNA. In this case, the test would still be valid as long as one or more positive signal(s) is detected on the array.
[0136] In another embodiment, the array cassette to be used in the flow-through process and/or device is of different forms and sizes. Instead of using the 10 dots array, a 35 dot is readily available whereas addition of dot can be used for detecting extra pathogens subtypes and/or more drug resistant strains caused by, for example, gene mutation. Signal can also be digitized using imaging system accompanying the hybridization device such as FT-Pro. In another embodiment, the hybridization device available is an auto-device with all analysis build-in with digitizing capability.
[0137] The present invention is advantageous over existing testing methods and kits because it can amplify multiple targets quantitatively and detect multiple targets simultaneously with high sensitivity, and covers 12 types of STD-causing pathogens including HPV subtypes which are excluded in most of the existing kits. Coupling with the flow-through hybridization process, the present invention allows a rapid, sensitive and high throughput detection of the STD-causing
pathogens.
HSV1/2 HSV_Pr1 (minus strand) CTTGTCGATCACCTCCTCG Amine 295
HPV6 HPV6JN2 TTATGTGCATCCGTAACTA Amine 296
HPV11 hPV11_Pr (minus strand) GTAGCAGATTTAGACACAGATG Amine 297
AC b-globin-402T AAGGTGAACGTGGATGAAGTTGGTGG Amine 298
Below are some example protocols for PCR and hybridization:
This thermal profile is suitable for the Veriti Thermal Cycler (Life technologies), S 1000 Thermal Cycler (Bio-rad). A modification of the cycling program may be necessary when using other thermal cyclers (ramp rate 3°C / sec).
One embodiment of hybridization protocol:
Blocking
Blocking 150 μΐ 5 min
Solution
25 °C
Enzyme Enzyme
150 μΐ 5 min
Conjugation Conjugate
Adjust Device Temperature (UP)
Post-reaction
A Solution 200 μί x 4 times
Wash
Detection
150 μΐ 3 min
Color Solution 36 °C
Development
A Solution 200 μΐ x 3 times
Stop Reaction Stop Solution 150 μΐ 1 min
EXAMPLE 6
Genotvping For Thrombophilia
[0138] The present invention also provides a method for detecting mutations related to thrombophilia, comprising the steps of: (a) obtaining a sample comprising a template nucleic acid; (b) amplifying the template nucleic acid with primers selected from the group consisting of SEQ ID NOs:299-306, thereby generating amplicons; and (c) hybridizing the amplicons with oligonucleotide probes selected from the group consisting of SEQ ID NOs:307-3 14, wherein the resulting hybridization profile would indicate the presence of mutations related to thrombophilia. In one embodiment, the primers comprise a signal generating label. In one embodiment, hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process. In one embodiment, the above method can detect mutation at a gene selected from the group consisting of Factor V Leiden, Factor II (Prothrombin), and Methylenetetrahydrofolate Reductase.
[0139] Figure 1 1 shows one embodiment of a Thrombophilia array. Figure 12 shows one example of visual interpretation of the Thrombophilia array.
Primer sequences:
Primer Probe sequence (5'-3') 5' Modification SEQ ID NO
FVL F GAAAATGATGCCCAGTGCTT 299
FVL R TTGAAGGAAATGCCCCATTA Biotin 300
FII F GAACCAATCCCGTGAAAGAA 301
FU R AGCTGCCCATGAATAGCACT Biotin 302
MTHFR677 F GGTTACCCCAAAGGCCACC Biotin 303
MTHFR677 R AAGCGGAAGAATGTGTCAGC Biotin 304
MTHFR1298_F TTTGGGGAGCTGAAGGACTA 305
MTHF 1298_R CTTTGTGACCATTCCGGTTT Biotin 306
Probe sequences:
Below are some example protocols for PCR and hybridization:
* Suggested range of total DNA is l Ong - 100 ng.
520 μί
Hybridization Hybridization Solution (500 μΐ 5 mins
+PCR Product + 20 μΐ)
41 °C
Stringent Wash Stringent Wash Solution 750 μΐ -
1 min
Stringent Wash Stringent Wash Solution 750 μΐ
x 3 times
Adjust Device Temperature (DOWN)
Blocking Blocking Solution 500 μΐ 5 mins
25 °C
Enzyme Conjugation Enzyme Conjugate 500 μΐ 5 mins
Adjust Device Temperature (UP)
Post-reaction Wash A Solution 750 μΐ x 4 times
Posting Blocking Blocking Solution 500 μΐ 1 min
Detection Solution 500 μΐ 36 °C 5 mins
Color Development
B Solution 750 μΐ x 3 times
Stop Reaction Stop Solution 750 μΐ 1 min
Claims
1 . A method for detecting the presence of sexually transmitted diseases causing pathogens in a subject, comprising the steps of:
(a) obtaining from the subject a sample comprising a template nucleic acid;
(b) amplifying the template nucleic acid with primers of SEQ ID NOs:263-286, thereby generating amplicons; and
(c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:287-298, wherein the resulting hybridization profile would indicate the presence of sexually transmitted diseases causing pathogens.
2. The method of claim 1 , wherein hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
3. The method of claim 1 , wherein the method can detect the presence of sexually transmitted diseases caused by an organism selected from the group consisting of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum, Herpes simplex virus 1 , Herpes simplex virus 2, Human papillomavirus type 6, and Human papillomavirus type 1 1 .
4. A kit for detecting the presence of sexually transmitted diseases causing pathogens in a subject, comprising primers of SEQ ID NOs:263-286 and oligonucleotide probes of SEQ ID Os: 287-298.
5. A method for detecting the presence of multidrug-resistant Mycobacterium tuberculosis (D -MTB), comprising the steps of:
(a) obtaining a sample comprising a template nucleic acid;
(b) amplifying the template nucleic acid with primers of SEQ ID NOs: 174-181 , thereby generating amplicons; and
(c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs: 182-200, wherein the resulting hybridization profile would indicate the presence of multidrug-resistant Mycobacterium tuberculosis.
6. The method of claim 5, wherein hybridization of the amplicons with the plurality of
oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
7. The method of claim 5, wherein the method can detect the presence of multidrug-resistant Mycobacterium tuberculosis having one or more of the following mutations:
one of seven mutations in the rpoB gene;
one of two mutations in the katG gene; and
one mutation in the inhA gene.
A kit for detecting the presence of multidrug-resistant Mycobacterium tuberculosis, comprising primers of SEQ ID NOs: 174- 1 81 and oligonucleotide probes of SEQ ID NOs: 182-200.
A method of detecting beta-globin mutations in a subject having beta-thalassemia, comprising the steps of:
(a) obtaining from the subject a sample comprising a template nucleic acid;
(b) amplifying the template nucleic acid with primers of SEQ ID NOs:201 -205, thereby generating amplicons; and
(c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:206-240, wherein the resulting hybridization profile would indicate the genotypes of beta-thalassemia.
The method of claim 9, wherein hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
The method of claim 9, wherein the method can detect one of twenty one beta-globin mutations.
12. A kit for detecting beta-globin mutations, comprising primers of SEQ ID NOs:201 -205 and oligonucleotide probes of SEQ ID NOs: 206-240.
13. A method for detecting the presence of HBV, comprising the steps of:
(a) obtaining a sample comprising a template nucleic acid;
(b) amplifying the template nucleic acid with primers of SEQ ID NOs:241 -244,
thereby generating amplicons; and
(c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:245-260, wherein the resulting hybridization profile would indicate the presence of HBV.
14. The method of claim 13, wherein hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
15. The method of claim 13, wherein the method can detect the presence of HBV having a genotype selected from the group consisting of HBV genotypes A to H.
16. A kit for detecting the presence of HBV, comprising primers of SEQ ID NOs:241 -244 and oligonucleotide probes of SEQ ID NOs: 245-260.
17. A method for detecting mutations related to thrombophilia, comprising the steps of:
(a) obtaining a sample comprising a template nucleic acid;
(b) amplifying the template nucleic acid with primers of SEQ ID NOs:299-306, thereby generating amplicons; and
(c) hybridizing the amplicons with oligonucleotide probes of SEQ ID NOs:307-314, wherein the resulting hybridization profile would indicate the presence of mutations related to thrombophilia.
18. The method of claim 17, wherein hybridization of the amplicons with the plurality of oligonucleotide probes is carried out in a flow-through process, a lateral flow-through process, or a reversed flow-through process.
19. The method of claim 17, wherein the method can detect mutation at a gene selected from the group consisting of Factor V Leiden, Factor II (Prothrombin), and Methylenetetrahydrofolate Reductase .
A kit for detecting the presence of mutations related to thrombophilia, comprising primers of SEQ ID NOs:299-306 and oligonucleotide probes of SEQ ID NOs: 307-314.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480027795.3A CN105392896B (en) | 2013-03-15 | 2014-03-17 | Quick and sensitive genotype identification and detection of nucleic acids |
HK16104123.4A HK1217515A1 (en) | 2013-03-15 | 2016-04-11 | Rapid and sensitive nucleic acid detection and genotyping |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791933P | 2013-03-15 | 2013-03-15 | |
US61/791,933 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014139330A1 true WO2014139330A1 (en) | 2014-09-18 |
Family
ID=51530464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/000275 WO2014139330A1 (en) | 2013-03-15 | 2014-03-17 | Rapid genotyping analysis and kits thereof |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN106906306B (en) |
HK (1) | HK1217515A1 (en) |
WO (1) | WO2014139330A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106290884A (en) * | 2015-06-15 | 2017-01-04 | 江苏戴格诺思生物技术有限公司 | A kind of Ureaplasma urealyticum gold mark detection kit and detection method |
CN108184327A (en) * | 2015-07-14 | 2018-06-19 | 雅培分子公司 | For identifying the composition of drug resistant M and method |
CN108660254A (en) * | 2018-05-30 | 2018-10-16 | 杭州千基生物科技有限公司 | Genital tract causal agent detection of nucleic acids primer, probe, kit and detection method |
WO2019152657A1 (en) * | 2018-02-03 | 2019-08-08 | Simple Healthkit, Inc. | Reliable, comprehensive, and rapid sexual health assessment |
WO2019154996A1 (en) * | 2018-02-09 | 2019-08-15 | Genincode Uk, Ltd. | Prediction of pregnancy loss |
US10975446B2 (en) | 2014-07-24 | 2021-04-13 | Abbott Molecular Inc. | Compositions and methods for the detection and analysis of Mycobacterium tuberculosis |
RU2750715C1 (en) * | 2020-12-23 | 2021-07-01 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Method for determining the genetic predisposition to the development of multidrug-resistant tuberculosis mycobacterium tuberculosis in hiv infection |
CN113416743A (en) * | 2021-07-26 | 2021-09-21 | 广东省农业科学院动物卫生研究所 | Nucleic acid molecule, PCR primer pair and kit for detecting avian trichomonas rpoB gene |
EP3957753A1 (en) * | 2014-10-10 | 2022-02-23 | Rutgers, the State University of New Jersey | Polymerase chain reaction primers and probes for mycobacterium tuberculosis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11015228B2 (en) * | 2018-01-09 | 2021-05-25 | Abbott Molecular Inc. | Assay for detecting Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium |
CN109457037A (en) * | 2018-10-24 | 2019-03-12 | 美林美邦(厦门)生物科技有限公司 | A kind of genital tract causal agent kit for detecting nucleic acid |
CN109487014B (en) * | 2019-01-09 | 2022-08-02 | 中生方政生物技术股份有限公司 | Herpes simplex virus II type detection marker, primer probe pair, kit and detection method |
CN111593112A (en) * | 2020-05-12 | 2020-08-28 | 深圳市星蝶科技有限公司 | PCR reagent and kit for detecting beta-thalassemia |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101553577A (en) * | 2006-04-04 | 2009-10-07 | 达雅高生物科技有限公司 | Rapid genotyping analysis and the device thereof |
CN102209793A (en) * | 2008-11-19 | 2011-10-05 | 达雅高生物科技有限公司 | Nucleotide sequences, methods and kits for detecting hpv |
WO2011139750A1 (en) * | 2010-04-29 | 2011-11-10 | Diagcor Bioscience Incorporation Limited | Rapid genotyping analysis for human papillomavirus and the device thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043035A (en) * | 1997-11-03 | 2000-03-28 | Rijks University Leiden | Method for determining a risk factor for thrombosis |
JP2007522804A (en) * | 2004-01-15 | 2007-08-16 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | A method developed for the identification of thrombus formation tendencies (MERT) |
CN101591700A (en) * | 2008-05-29 | 2009-12-02 | 北京华安佛医药研究中心有限公司 | A kind of test kit, method and purposes of predicting the thrombosis disease occurrence risk |
CN101864479A (en) * | 2009-04-17 | 2010-10-20 | 吴奇涵 | Application, detection method and kit of MTHFR (Methylene Tetrahydrofolate Reductase) gene SNP (Single Nucleotide Polymorphism) guide folic acid and related nutrient element intake |
CN102732600A (en) * | 2011-04-13 | 2012-10-17 | 上海芯超生物科技有限公司 | Genetic evaluation and suit method for individualized tumor therapy |
CN102851365A (en) * | 2012-08-31 | 2013-01-02 | 唐爱发 | Primers, kit and method for identification of polymorphism of C677T of human MTHFR gene |
-
2014
- 2014-03-17 CN CN201611054755.5A patent/CN106906306B/en active Active
- 2014-03-17 WO PCT/CN2014/000275 patent/WO2014139330A1/en active Application Filing
- 2014-03-17 CN CN201480027795.3A patent/CN105392896B/en not_active Expired - Fee Related
-
2016
- 2016-04-11 HK HK16104123.4A patent/HK1217515A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101553577A (en) * | 2006-04-04 | 2009-10-07 | 达雅高生物科技有限公司 | Rapid genotyping analysis and the device thereof |
CN102209793A (en) * | 2008-11-19 | 2011-10-05 | 达雅高生物科技有限公司 | Nucleotide sequences, methods and kits for detecting hpv |
WO2011139750A1 (en) * | 2010-04-29 | 2011-11-10 | Diagcor Bioscience Incorporation Limited | Rapid genotyping analysis for human papillomavirus and the device thereof |
US20130244887A1 (en) * | 2010-04-29 | 2013-09-19 | Diagcor Bioscience Incorporation Limited | Rapid genotyping analysis and devices thereof |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975446B2 (en) | 2014-07-24 | 2021-04-13 | Abbott Molecular Inc. | Compositions and methods for the detection and analysis of Mycobacterium tuberculosis |
US11932911B2 (en) | 2014-07-24 | 2024-03-19 | Abbott Molecular, Inc. | Compositions and methods for the detection and analysis of Mycobacterium tuberculosis |
EP3957753A1 (en) * | 2014-10-10 | 2022-02-23 | Rutgers, the State University of New Jersey | Polymerase chain reaction primers and probes for mycobacterium tuberculosis |
CN106290884A (en) * | 2015-06-15 | 2017-01-04 | 江苏戴格诺思生物技术有限公司 | A kind of Ureaplasma urealyticum gold mark detection kit and detection method |
US10526664B2 (en) | 2015-07-14 | 2020-01-07 | Abbott Molecular Inc. | Compositions and methods for identifying drug resistant tuberculosis |
EP3322483A4 (en) * | 2015-07-14 | 2019-01-02 | Abbott Molecular Inc. | Compositions and methods for identifying drug resistant tuberculosis |
US11225693B2 (en) | 2015-07-14 | 2022-01-18 | Abbott Molecular Inc. | Compositions and methods for identifying drug resistant tuberculosis |
CN108184327A (en) * | 2015-07-14 | 2018-06-19 | 雅培分子公司 | For identifying the composition of drug resistant M and method |
US10794911B2 (en) | 2018-02-03 | 2020-10-06 | Simple Healthkit, Inc. | Reliable, comprehensive, and rapid sexual health assessment |
WO2019152657A1 (en) * | 2018-02-03 | 2019-08-08 | Simple Healthkit, Inc. | Reliable, comprehensive, and rapid sexual health assessment |
US11782060B2 (en) | 2018-02-03 | 2023-10-10 | Simple Healthkit, Inc. | Reliable, comprehensive, and rapid sexual health assessment |
WO2019154996A1 (en) * | 2018-02-09 | 2019-08-15 | Genincode Uk, Ltd. | Prediction of pregnancy loss |
CN108660254A (en) * | 2018-05-30 | 2018-10-16 | 杭州千基生物科技有限公司 | Genital tract causal agent detection of nucleic acids primer, probe, kit and detection method |
CN108660254B (en) * | 2018-05-30 | 2023-07-28 | 杭州千基生物科技有限公司 | Primer, probe, kit and method for detecting genital tract pathogen nucleic acid |
RU2750715C1 (en) * | 2020-12-23 | 2021-07-01 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Method for determining the genetic predisposition to the development of multidrug-resistant tuberculosis mycobacterium tuberculosis in hiv infection |
CN113416743A (en) * | 2021-07-26 | 2021-09-21 | 广东省农业科学院动物卫生研究所 | Nucleic acid molecule, PCR primer pair and kit for detecting avian trichomonas rpoB gene |
CN113416743B (en) * | 2021-07-26 | 2023-06-16 | 广东省农业科学院动物卫生研究所 | Nucleic acid molecule, PCR primer pair and kit for detecting trichomonas fowl rpoB gene |
Also Published As
Publication number | Publication date |
---|---|
CN106906306B (en) | 2020-07-10 |
CN105392896B (en) | 2017-10-20 |
HK1217515A1 (en) | 2017-01-13 |
CN106906306A (en) | 2017-06-30 |
CN105392896A (en) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014139330A1 (en) | Rapid genotyping analysis and kits thereof | |
US8980555B2 (en) | Rapid genotyping analysis and devices thereof | |
CA2689306C (en) | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system | |
JP6574703B2 (en) | Method for detecting Helicobacter pylori DNA in stool samples | |
JP2010521156A (en) | System and method for detection of HIV drug resistant variants | |
WO2020199441A1 (en) | Use of primer probe combination and kit thereof in hbv detection | |
EP3214181B1 (en) | Oligonucleotides, set of oligonucleotides, htlv-i/htlv-ii infection diagnostic and discrimination kit, polynucleotide suitable as reference target for designing primers and probes for the detection and differentiation of htlv-i and htlv-ii, amplicon and method for detecting at least one htlv target | |
CN114085929B (en) | Kit for detecting African swine fever virus wild strain and vaccine strain | |
WO2023279042A2 (en) | Compositions and methods for detection of severe acute respiratory syndrome coronavirus 2 variants | |
US20070031828A1 (en) | Assay | |
CN109182493A (en) | The primer and kit and its detection method of people's 16p11.2 microdeletion syndrome detection | |
KR101287431B1 (en) | Primer composition for amplifying genetic region having various genetic variations in target genes, method for amplifying the target genes using the same, PCR amplification kit comprising the same and method for analyzing the genotype of the target genes | |
CN110863066A (en) | Kit for detecting five TORCH pathogens and application thereof | |
RU2715625C1 (en) | Set of oligonucleotide primers and a fluorescence-labeled probe for identifying a west nile virus 1 genotype | |
CN109517929B (en) | Primer group and kit for porcine circovirus detection and type2 typing | |
RU2715617C1 (en) | Set of oligonucleotide primers and a fluorescence-labeled probe for identifying a west nile virus genotype 2 | |
JP2004538010A5 (en) | ||
JP5898831B2 (en) | Detection of human papillomavirus | |
US20240209464A1 (en) | Pathogen Detection From Urine Analyte in All Gender Patients | |
US20230278029A1 (en) | Multiplex cartridge for detection of viral nucleic acids and human or animal snps | |
Seo et al. | Rapid and specific detection of Trichophyton rubrum and Trichophyton mentagrophytes using a loop-mediated isothermal amplification assay | |
Saini et al. | Evaluation of polymerase chain reaction (PCR) method and hybrid capture II (HCII) assay for the detection of human papillomavirus in cervical scrapings | |
CN107164562B (en) | Diarrhea-associated virus multiple gene detection system and kit and application thereof | |
US20160153060A1 (en) | Method for species identification by using molecular weights of nucleic acid cleavage fragments | |
WO2024145234A1 (en) | Pathogen detection from urine analyte in all gender patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480027795.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14762786 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14762786 Country of ref document: EP Kind code of ref document: A1 |